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 The Moloney murine leukemia virus (MoMLV) particle is composed of 
roughly 2,500 Gag polyproteins, 125 Gag-Pol polyproteins, and precisely two 
copies of genomic RNA (gRNA) in the form of a dimer. The Gag polyprotein is 
responsible for directing MoMLV assembly and for recruiting both Gag-Pol and 
the gRNA dimer for incorporation during assembly. Each of the thousands of Gag 
molecules in a MoMLV particle contains the domains required to bind both Gag-
Pol and gRNA. The mechanisms that account for the conserved asymmetrical 
numerical proportions of these molecules are unknown. The goal of this 
dissertation was to examine the parameters that define the molecular proportions 
of Gag, Gag-Pol, and the gRNA dimer in the MoMLV particle. 
 In order to test the hypothesis that only a small number of Gag molecules 
within the MoMLV particle are required to recruit gRNA for incorporation during 
MoMLV assembly, MoMLV particles were produced that contained variable 
proportions of two types of Gag molecules: one that was able to participate in 
high-affinity gRNA packaging interactions and one that was not. Utilizing these 
mixed particles, results showed that MoMLV gRNA was packaged in the absence 
of a full complement of packaging competent Gag. 
 To test the hypothesis that the molecular counting mechanism responsible 
for incorporating MoMLV Gag-Pol and the gRNA dimer are distinct, an 
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experimental system was constructed that allowed the proportion of Gag to Gag-
Pol and Gag to gRNA to be manipulated. Using this system, our results showed 
that the incorporation of Gag-Pol into MoMLV is a stochastic process that is 
dependent on intracellular expression ratios. In contrast, incorporation of gRNA 
was shown to be a non-random and saturable, thus not strictly dependent of 
intracellular expression ratios. These results support a model whereby the 
proportions of Gag and Gag-Pol co-assembled are determined by a distinct 









Moloney murine leukemia virus 
 Retroviruses are defined by a remarkable replication cycle. The retrograde 
flow of genetic information from genomic RNA to DNA during reverse 
transcription and the integration of the proviral DNA product into the host cell 
chromosomal DNA are the major defining characteristics of the retrovirus family 
Retroviridae (23, 42). 
Classification and nomenclature 
 The family Retroviridae is divided into seven genera based on genetic 
structure and morphology: alpharetrovirus, betaretrovirus, gammaretrovirus, 
deltaretrovirus, epsilonretrovirus, lentivirus, and spumavirus. Moloney murine 
leukemia virus is a representative member of the gammaretrovirus genus, 
whereas human immunodeficiency virus type-1 (HIV-1), the well-studied human 
pathogen, is a representative member of the lentivirus genus (129). 
 Murine leukemia viruses are further classified by their cell tropism. 
Ecotropic viruses infect only cells of their characteristic host species. For 
example, the ecotropic MoMLV infects cells of mouse or rat origin. Xenotropic 
murine leukemia viruses infect cells of non-rodent origin, and amphotropic or 
polytropic viruses infect both rodent cells and cells of other species (23). 
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 Based on its genetic structure, MoMLV is part of a group of retroviruses 
commonly known as “simple” retroviruses. MoMLV’s relatively simple RNA 
genome contains only three genes: gag, pol, and env. These three genes are 
conserved among all retroviruses and encode the viral structural proteins and 
viral enzymes. In contrast, HIV-1 is part of a group known as  “complex” 
retroviruses because in addition to gag, pol, and env, a complex retrovirus’ 
genome contains additional accessory genes (23, 42). The work described in this 
dissertation utilizes MoMLV, which has been used as a model system in 
retrovirology for over 50 years. 
Pathogenesis 
 MoMLV is an oncogenic retrovirus that induces tumors in its murine host 
(32, 77). It was first isolated from mouse sarcoma tissue in 1960 by its 
namesake, John Moloney (88). MoMLV induces T-cell lymphoma in infected 
mice by activating cellular proto-oncogenes in infected cells (reviewed in (32)). 
Typically, cellular proto-oncogenes, such as prim-1, or c-myc in the case of 
MoMLV, are activated due to the insertion of proviral DNA in close proximity to 
an oncogene (32). Insertional activation of proto-oncogenes by MoMLV results in 
the development of lymphoma in mice within months of infection at a very high 
rate of incidence (88). 
The MoMLV RNP 
 Retroviruses are ribonucleoprotein (RNP) complexes comprised of RNA 
and protein, surrounded by a lipid envelope. The major RNA component of the 
MoMLV RNP is two copies of the viral RNA genome, and the major protein 
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component of the RNP is the viral structural polyprotein Gag. The major as well 
as minor components of the MoMLV RNP will be discussed in the following 
section. 
MoMLV RNAs 
 The template for transcription of MoMLV RNA is the integrated proviral 
DNA (Fig I-1A).  Structurally, the proviral DNA consists of identical 5’ and 3’ long 
terminal repeats (LTRs) flanking the internal coding sequence (124, 138). The 
LTRs consist of three regions termed U3 (3’ unique), R (direct repeat), and U5 (5’ 
unique). The U3 region of the 5’ LTR contains the promoter and enhancer 
elements required for transcription initiation. Within the coding sequence, gag 
and pol are present in the same open reading frame, while env is present in a 
separate reading frame that overlaps slightly with the gag/pol reading frame at its 
5’ end. 
 Transcription of the full-length viral RNA is mediated by the host cell RNA 
polymerase II and is defined by a start site at the first base of the 5’ R region and 
the cleavage and polyadenylation site immediately downstream the 3’ R region 
(Fig I-1A). Like most cellular mRNAs, the viral transcript is subject to post-
transcriptional processing events including 5’ capping and 3’ poly(A) tail addition. 
The resulting sense-stranded transcript is ~8.3kb in length and is flanked by 5’ 
and 3’ untranslated regions (UTRs). The full-length transcript serves two 
functions: (i) to serve as mRNA from which gag and gag-pol are expressed and 









Figure I-1: MoMLV RNAs and polyproteins. (A) Schematic diagram of both the 
MoMLV full-length RNA and the spliced env mRNA, which are derived from the 
proviral DNA. Abbreviations include: 3’ unique sequence (U3), direct repeat 
sequence (R), 5’ unique sequence (U5), “Psi” or Packaging Signal (Ψ), splice 
donor site (SD), and splice acceptor site (SA). (B) Polyprotein products of 
MoMLV RNAs. The Gag (group specific antigen) polyprotein consists of the 
following domains: matrix (MA), p12 late domain, capsid (CA), and nucleocapsid 
(NC). Gag-Pol consists of the Gag domains as well as the Pol (polymerase) 
domains, including: protease (PR), reverse transcriptase (RT), and integrase 
(IN). The Env (envelope) polyprotein consists of the surface (SU) and 
transmembrane (TM) domains. 
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 Alternative splicing of the primary full-length viral RNA transcript yields 
additional sub-genomic mRNAs. The sub-genomic env mRNA is produced 
via removal of the sequence between the splice donor (SD) and splice acceptor 
(SA) sites by the host-cell splicing machinery (Fig I-1A). Furthermore, removal of 
the sequence between an alternative SD site (SD’) and SA produces a 4.4kb 
sized sub-genomic mRNA that may be important for MoMLV replication (28, 55).  
 Downstream of the SD site, within the 5’ UTR of the full-length transcript, 
is a sequence termed psi (Ψ) for “packaging signal” (80) (Fig I-1A). Ψ functions 
as a cis-acting packaging signal during recruitment and incorporation of gRNA 
into assembling virions (34, 80, 93). Due to Ψ’s position downstream of SD but 
upstream of SD’, RNA splicing removes it from the env mRNA. However, Ψ is 
maintained in the 4.4kb sub-genomic transcript, which therefore may be 
incorporated into assembling virions (28, 55, 81). The role of Ψ in RNA 
packaging and virus assembly are discussed in greater detail in a dedicated 
section later in this chapter.  
MoMLV polyproteins 
 Retroviruses have maximized the coding capacity of their relatively 
compact genomes by coordinating the expression of multiple proteins from a 
single RNA. The full-length MoMLV transcript (Fig I-1A) serves as mRNA for the 
production of three polyproteins: Gag (Pr65Gag), Gag-Pol (Pr180Gag-Pol), and 
glyco-Gag (gPr80Gag) (Fig I-1A and B). Gag-Pol is produced when the Gag stop 
codon is occasionally read-through via termination suppression. The resulting 
Gag-Pol fusion is identical to Gag in its N-terminus. Glyco-Gag is produced by 
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occasional transcription initiation at the atypical CUG start codon upstream of the 
Gag AUG start codon, and is modified by glycosylation post-translationally. The 
sub-genomic env transcript serves as mRNA for the production of the single Env 
polyprotein (gPr80Env) (Fig I-1B). 
 The retroviral polyproteins consist of smaller proteins that are liberated by 
proteolytic cleavage, further adding to the coding capacity of compact retroviral 
genomes. For MoMLV, the structural polyprotein Gag is cleaved into four 
proteins: matrix (MA or p15), p12, capsid (CA or p30), and nucleocapsid (NC or 
p10) (Fig I-1B). MoMLV Gag-Pol polyprotein processing liberates the four Gag 
proteins in addition to the three Pol proteins, including: protease (PR or p14), 
reverse transcriptase (RT or p80), and integrase (IN or p46) (Fig I-1B). The 
MoMLV Env polyprotein is processed into the surface glycoprotein (SU or gp70) 
and the transmembrane domain (TM or p15E) protein (Fig I-1B). 
Virion structure 
 Cryo-electron microscopy reveals that the MoMLV particle is roughly 
spherical, with a diameter of ~100-120nm (144), and like all retroviruses it is 
surrounded by an envelope derived from the host cell plasma membrane (Fig I-
2). For newly assembled immature viral particles, the inner leaflet of the viral 
envelope is lined with a layer of hexameric Gag rings arranged in a 
paracrystalline lattice (144). Gag-Pol polyproteins are also present within the 




Figure I-2: MoMLV particle structure. Stylized depictions of an immature 
(left) and mature (right) MoMLV virion. The viral protein components 
depicted here include Env, Gag, and Gag-Pol. The viral RNA component 
depicted here includes a single gRNA dimer, consisting of two gRNAs 
connected in a dimer linkage toward their 5’ ends. Also depicted here are 
host cell non-coding RNAs. 
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the interior of the viral particle and are associated with the Gag polyprotein lattice 
(Fig I-2A). Studding the viral envelope are the envelope proteins, consisting of 
the SU and TM domains. 
 Proteolytic processing of the Gag and Gag-Pol polyproteins during particle 
maturation by PR results in a dramatic rearrangement of the interior components 
of the MoMLV particle (Fig I-2). MA remains associated with the viral envelope 
while CA condenses to form a pleiomorphic but generally spherical protein core 
(144). NC is found associated with the viral gRNA inside the CA core along with 
the viral enzymes RT and IN. 
Host Cell RNAs 
 Host cellular RNAs are also present within retroviral RNPs (Fig I-2). 
MoMLV selectively packages many host cellular non-coding RNAs, including for 
example: 7SL RNA, mY RNAs, U6 snRNA, and tRNApro (99). 7SL RNA is the 
structural component of the signal recognition particle (SRP), which is 
responsible for targeting secretory and membrane proteins to the endoplasmic 
reticulum (63). mY RNAs are present in cells within RNPs called RoRNPs that 
have been implicated in playing a role in RNA quality control (20). U6 snRNA 
functions during pre-mRNA splicing as part of the cell spliceosome complex 
(136). With the exception of tRNApro, which primes the reverse transcription 
reaction (78), the functions of these RNAs in MoMLV replication are unknown. 
MoMLV replication cycle 
 The retroviral replication cycle may be divided into two phases: early and 
late. The early events consist of: (i) attachment and entry, (ii) reverse 
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transcription, (iii) nuclear entry, and (iv) integration. The late events consist of: (i) 
transcription, (ii) RNA processing and nuclear export, (iii) translation, (iv) 
assembly and RNA packaging, and (v) release and maturation (Fig I-3). 
Early events 
 The MoMLV replication cycle begins with entry of the viral RNP into the 
host cell. Entry is initiated by interactions between the viral envelope proteins and 
the host cell surface receptor, which in the case of ecotropic MoMLV is the cell 
surface cationic amino acid transporter mCAT-1 (1, 67). Host cell attachment, 
mediated by receptor interactions, is followed by fusion of the viral envelope with 
the host cell plasma membrane, thereby allowing the viral core and its contents 
access to the host cell cytoplasm. 
 Following internalization, the MoMLV CA core dissociates in a process 
known as uncoating, a mechanism which is poorly understood in retroviruses, 
even for the well-studied HIV-1 (2). Next, the single-stranded RNA genome is 
converted to double-stranded DNA (dsDNA) in the reverse transcription reaction 
catalyzed by the viral RT enzyme. Subsequently, the viral dsDNA is transported 
to the nucleus as part of a pre-integration complex (PIC) comprised of partially 
disassembled CA core,NC, and IN (8). Recent studies have shown that the viral 
p12 protein binds the viral dsDNA and is an important component of the MLV PIC 
(109). Interestingly, MoMLV PICs are only able to gain access to the host cell 
nucleus when the nuclear membrane dissociates during mitosis (74, 115). 
Consequently, productive MoMLV infection occurs concurrent with cell cycle 




Figure I-3: MoMLV replication cycle. The MoMLV replication cycle can be 
separated into two major phases: early and late. The early phase steps depicted 
here include: (1) attachment of the MoMLV virion to the host cell, (2) entry of the 
viron contents into the host cell cytoplasm, (3) reverse transcription of the viral 
gRNA into dsDNA, and (4) integration of the viral dsDNA into the host cell 
genome. The late phase steps depicted here include: (5) transcription of the 
MoMLV RNA from the integrated provirus, (6) translation of the viral polyproteins 
from the viral RNAs, (7) assembly of viral proteins and gRNAs at the host cell 




 Once inside the nucleus, the proviral DNA is inserted into the host cell 
chromosomal DNA in a stepwise process known as integration (73). The viral  
enzyme IN catalyzes the host DNA strand cutting and viral DNA joining reactions. 
Genome-wide studies of retroviral integration have revealed a preference for 
MoMLV proviral DNA insertion within the transcriptional start sites of active 
genes (85, 143). Integration is an essential and defining characteristic of the 
retroviral replication cycle, since the late replication events are completely 
dependent on this step. 
Late events 
 Late events of the MoMLV replication cycle begin with the transcription of 
the full-length MoMLV RNA (described above) from the proviral DNA by the host 
cell transcriptional machinery. In a manner similar to cellular mRNAs (65), the 
viral RNA must by extensively processed prior to nuclear egress. Processing 
includes 5’-cap addition, 3’-end cleavage, and poly(A) tail addition. In addition, 
RNA splicing produces the sub-genomic viral RNAs. Following processing, the 
viral RNAs are exported to the cytoplasm via an undefined trafficking pathway. 
However, some studies suggest that sequences within the 5’-UTR, including Ψ, 
may function in nuclear export, at least in the case of full-length viral RNA (4). 
 Nuclear export of viral RNAs is followed by translation of the MoMLV 
polyproteins Gag, Gag-Pol, and Env. For cellular mRNAs, translation typically 
initiates when the ribosome recognizes the 5’-cap and scans towards the 3’ end 
until the first AUG start codon is reached. However, some evidence suggests this 
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ribosome scanning mechanism may not be utilized in the case of retroviral 
translation, due to the high degree of secondary structure present in the leader 
region of viral RNAs. For MoMLV, an internal ribosome entry site (IRES) within 
the RNA may exist that allows the ribosome to avoid sequences upstream of gag 
(7).  
 Next, the Gag and Gag-Pol polyproteins are targeted to sites of virus 
assembly at the host cell plasma membrane, along with two copies of gRNA 
coupled in an RNA dimer. The role of Gag in virus assembly, gRNA dimerization, 
and packaging will be discussed in greater detail in the following section. The 
Env glycoprotein is also targeted to the host cell plasma membrane. However, 
Env is translated by ribosomes on the ER and shuttled into the host cell secretory 
pathway, thereby ensuring host cell surface expression. 
 Finally, following assembly of the MoMLV RNP complex at the host cell 
plasma membrane, newly forming virions are released from the host cell into the 
extracellular space in an ESCRT-dependent manner (107). At this point, PR- 
mediated proteolytic polyprotein processing liberates the subdomains of Gag and 
Gag-Pol, thereby rendering the newly formed virus particle fully infectious and 
primed to repeat the replication cycle in a new host cell. 
MoMLV Assembly 
 The association of Gag polyproteins induces assembly of retroviral 
particles. In addition to the four structural domains, MoMLV Gag contains three 
functional domains important for assembly: (i) MA targets Gag to sites of 
assembly; (ii) CA mediates Gag-Gag multimerization interactions; and (iii) NC 
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binds RNA, which in turn promotes additional Gag-Gag interactions. The 
integration of these simultaneous interactions drives particle formation. 
Gag PM targeting 
 Retroviruses bud from the host cell plasma membrane (PM). MoMLV Gag 
interactions with the PM are mediated by co-translational myristylation of the N-
terminus of MA (52, 113). The current model for PM binding posits that the 
myristyl moiety in Gag is initially inaccessible for PM interactions due to the 
conformation of MA. Interactions with the phospholipids PI(4,5)P2 
(phosphatidylinositol 4,5-bisphosphate) and PS (phosphatidylserine) on the inner 
leaflet of the PM are thought to expose and stabilize the myristyl moiety, thereby 
allowing insertion in and docking to the PM. MA-mediated attachment of Gag to 
the PM is thought to be followed by lateral movement of the molecules to lipid 
rafts or other microdomains where budding occurs (48). In addition to the myristyl 
moiety, a conserved region within MA known as the highly basic region (HBR) is 
also predicted to play a role in membrane binding (94). Interestingly, glyco-Gag 
also increases the release of MoMLV at lipid rafts, suggesting a role for glyco-
Gag in PM targeting (97). 
Gag multimerization 
 During assembly, the immature MoMLV particle is stabilized by lateral 
interactions between Gag polyproteins within a structural lattice. These Gag-Gag 
interactions occur primarily within the CA domain of Gag (37). MoMLV CA 
contains two domains, a tapered N-terminal domain (CA-NTD) and globular C-
terminal domain (CA-CTD) (90). Gag molecules are linked by contacts between 
 
 14 
CA-NTDs within Gag hexamers, the primary unit of the structural lattice (90). The 
CA-CTD contains a conserved domain known as the major homology region 
(MHR), and mutations within this domain impair virus assembly (140). Structural 
data confirms that the CA-CTD joins neighboring Gag hexamers within the lattice 
(36). 
 The NC domain of Gag also promotes Gag multimerization during 
assembly via so-called nonspecific interactions with RNAs (110). Purified 
recombinant retroviral Gag proteins only assemble into virus like particles (VLPs) 
in vitro with the addition of RNA (15). Moreover, deletion of the NC domain of 
MoMLV Gag results in a severe defect in virus assembly in cells (92). These 
results implicate RNA as a key co-factor in MoMLV assembly and suggest that 
Gag-RNA interactions are as important to MoMLV assembly as the Gag-Gag and 
Gag-PM interactions described above. 
Gag-Pol Incorporation 
 The CA domain of MoMLV Gag is thought to be important for Gag-Pol 
incorporation into newly forming virions, in a manner similar to that for HIV-1 
(reviewed in (53)). With HIV-1, Gag-Pol incorporation is dependent on sequences 
within the CA regions of Gag and Gag-Pol (56, 128). Although CA-CA 
interactions are thought to be the primary route for incorporation of Gag-Pol, Pol 
proteins can be incorporated into virions outside of the context of Gag-Pol for 
both HIV-1 and MoMLV (14, 17). For HIV-1, Gag-Pol initially multimerizes with 
Gag in the cytoplasm (47, 70), and this is followed by Gag-dependent targeting to 
sites of assembly at membranes (21, 104, 125). Viral RNA plays an important 
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role in facilitating Gag/Gag-Pol interactions (66), presumably by facilitating Gag-
Gag multimerization and not by direct gRNA/Gag-Pol interactions (66). 
MoMLV gRNA packaging 
 Retroviruses selectively incorporate gRNA into assembling virions from a 
cellular RNA pool, where viral gRNAs are vastly outnumbered by host mRNAs. 
The selective enrichment of gRNA in retroviral particles is due to specific cis-
acting packaging elements on the gRNA and trans-acting packaging elements on 
the Gag polyprotein. 
Cis-acting packaging elements 
 As described above, the cis-acting gRNA packaging signal, or Ψ, is 
contained within the 5’-UTR from nucleotides 215-565 (Fig I-1) (80). This highly 
structured region of the 5’-UTR is termed the “classic Ψ” and is comprised of a 
series of stem loops, including: DIS-1 and DIS-2 (dimerization initiation site 1 and 
2), and SL-C an SL-D (stem loop C and D). Mutations or deletions of Ψ abrogate 
gRNA packaging (34, 80, 93) whereas reinsertion of Ψ toward the 3’ end of the 
genome has been shown to restore gRNA packaging (79). Nucleotides 310-374, 
which encompass SL-C and SL-D, are termed the core encapsidation signal 
(CES), and are sufficient to direct packaging of heterologous RNAs (91). 
However, gRNA packaging is most efficient with an intact “classic Ψ” element 
and additional downstream nucleotides (5). Interestingly, a 17bp element 
downstream of the env stop codon toward the 3’ end of the genome has also 




Trans-acting packaging elements 
 The retroviral trans-acting gRNA packaging element is the NC domain of 
Gag (reviewed in (110)). MoMLV NC contains a single RNA binding domain 
characterized by a conserved “zinc-knuckle” motif (C-X2-C-X4-H-X4-C; C=Cys, 
H=His, X=variable) (51). Mutations within the “zinc-knuckle” motif of NC disrupt 
virus assembly, gRNA packaging, and infectivity (43, 46, 83, 92, 111). 
Additionally, treatment of retroviral particles with zinc-ejecting chemotherapeutic 
agents inhibits infectivity (114). 
gRNA dimerization 
 Retroviruses selectively package two copies of their RNA genomes joined 
by a dimer linkage. Electron microscopy studies originally demonstrated that 
gRNAs isolated from MoMLV are linked toward their 5’ ends (95). Subsequent 
studies confirmed that gRNA dimers are coupled by specific sequences within 
the 5’ UTR known as the dimer linkage site (DLS). The MoMLV DLS has been 
defined by the stem loops DIS-1 and DIS-2 from nucleotides 204-208 and 283-
298 within the 5’ UTR (76). The positioning of the DLS such that it overlaps with 
Ψ ensures that gRNA dimerization and packaging are functionally linked 
(reviewed in (25)). 
 The MoMLV Ψ/DLS contains several high affinity NC binding sites defined 
by conserved Py-Py-Py-G (Py=pyrimidine, G=guanosine) sequences (26, 29). 
Within the gRNA monomer, the high affinity NC binding sites are sequestered by 
base pairing interactions. However, the stepwise process of dimerization, 
whereby initial intermolecular base pair “kissing interactions” between DIS loops 
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on separate RNAs are followed by the formation of stable extended 
intermolecular dimer interface interactions, results in the exposure of high-affinity 
NC binding sites (25, 40, 76, 86, 87). The conversion of packaging-incompetent 
RNA monomer to packaging-competent RNA dimer represents a molecular 
“switch” that ensures selective engagement of dimers for packaging by NC (25). 
Sub-cellular localization 
 The sub-cellular site of gRNA dimerization likely differs among 
retroviruses (reviewed in (60)). The frequency of genetic marker reassortment 
between coexpressed retroviral gRNAs suggests that MoMLV gRNA dimerization 
occurs at or near sites of transcription in the nucleus, whereas HIV-1 gRNA 
dimerization occurs later in the cytoplasm (reviewed in (100)). The location of 
initial Gag-gRNA dimer interactions is unknown. However, in the case of HIV-1, 
recent studies suggest that a small number of Gag molecules engage the gRNA 
dimer in the cytoplasm prior to trafficking to sites of assembly at the PM (61, 69). 
MoMLV RNP Stoichiometry 
 Recent studies with HIV-1 have allowed the stoichiometry of retroviral 
RNP constituents to be refined (reviewed in (10)). The following section 
summarizes our current knowledge regarding the copy numbers of major protein 
and RNA components of the retroviral RNP. Most stoichiometric studies have 





 Initial estimates of the stoichiometry of Gag were based on cryo-electron 
tomography and scanning transmission EM (STEM) of in vitro-assembled 
envelope-free HIV-1 Gag particles (12). For an average immature 145 nm 
particle, the calculated number of Gag molecules was ~5,000 per particle (12). 
This estimate was updated when cryo-electron tomography of in vivo-assembled 
HIV-1 particles demonstrated that membrane bound particles contain an 
incomplete spherical Gag lattice shell (11, 142). Presumably, gaps in the Gag 
lattice shell of in vivo-assembled HIV-1 particles permit membrane curvature 
during virus budding (10). Reflecting the incompleteness of the Gag shell, newer 
estimates place the number of Gag molecules per particle at ~2,500 for an 
average 130 nm particle (16). 
Gag-Pol 
 The number of Gag-Pol molecules per HIV-1 particle was determined to 
be ~5% the number of Gag molecules (141). Calculations based on this number 
suggest that each particle would contain ~125 Gag-Pol molecules per the 
average ~2,500 Gag particle (16). Unlike MLV, the HIV-1 pol reading frame is 
offset from the gag reading frame by -1 nucleotide. This necessitates a -1 
ribosomal frameshift to translate the HIV-1 Gag-Pol polyprotein (57). The 
translation frameshift occurs ~5% of the time at a “slippery” sequence at the end 




 For MLV, readthrough of the gag stop codon to produce Gag-Pol also 
occurs at a frequency of ~5% (reviewed in (50)), resulting in the same 20:1 ratio. 
The correlation between the number of Gag-Pol molecules per HIV-1 particle 
(~5% relative to Gag) and the frameshift frequency (~5%) suggests that the 
incorporation of HIV-1 Gag-Pol into assembling virions is stochastic.  
 The mechanism that regulates readthrough frequency of the MLV gag 
stop codon was recently elucidated. Downstream of the gag stop codon is an 
RNA pseudoknot structure that is responsible for directing recoding of the stop 
codon (reviewed in (9)). New NMR-based structural data suggest that the RNA 
pseudoknot can adopt either of two conformations: (i) a nonpermissive 
conformation where readthrough is prevented, or (ii) a conformation that is 
permissive for readthrough. Consistent with the protein ratios observed during 
virus replication, the NMR structural studies showed that at physiological pH, the 
readthrough-permissive conformation is present at a frequency of ~5% in the 
total RNA (54). 
 Conservation of the strict 20:1 Gag:Gag-Pol expression ratio in HIV-1 and 
MLV suggest that maintenance of this ratio is important for virus replication. 
Indeed, studies where the Gag:Gag-Pol ratio have been disrupted result in 
defects in virus assembly and infectivity for both HIV-1 (31, 62, 103, 121) and 
MLV (33). 
gRNA 
 Although it has been known for decades that retroviruses package their 
gRNAs as dimers, only with advances in fluorescence microscopy that allow 
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single-RNA-molecule sensitivity has the precise number of dimers present within 
a particle been determined experimentally. Chen et al. showed that HIV-1 
particles, produced in cells where two uniquely labeled viral RNAs were 
coexpressed, were heterozygous in proportions that suggested random RNA 
assortment and the packaging of precisely one dimer (19). 
 The precise mechanism by which the single gRNA dimer specificity is 
achieved is unknown. Presumably, RNA size constraints are not involved in 
regulating the packaging of a single dimer, since gRNAs three times the normal 
length may be incorporated into virions (123). However, experiments do suggest 
that packaged gRNAs may be “counted” by their dimer linkage. When HIV-1 
Ψ/DLS is duplicated on the gRNA, monomeric RNAs appear in assembling 
virions (117, 118). 
Dissertation Overview 
 This dissertation addresses the mechanisms involved in determining the 
stoichiometry of MoMLV RNP constituents. I sought to examine the parameters 
that define the molecular proportions of Gag, Gag-Pol, and the gRNA dimer in 
the MoMLV RNP.  
 In the work described in this dissertation, there is a particular focus on 
questions surrounding numerical asymmetries between Gag, Gag-Pol, and 
gRNA within the RNP. For example, in Chapter II, I tested the hypothesis that 
only a small numerical proportion of Gag molecules within the MoMLV RNP are 
required to recruit gRNA for packaging during MoMLV assembly. To test this 
hypothesis, I produced MoMLV particles containing variable proportions of two 
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types of Gag molecules: one that is able to participate in high-affinity gRNA 
packaging interactions and one containing mutant NC that is not. Using this 
experimental system, I showed that MoMLV gRNA is packaged in the absence of 
a full complement of packaging competent Gag. 
 Next, in Chapter III I sought to examine the mechanism that accounts for 
the asymmetric proportions of Gag and Gag-Pol as well as Gag and the gRNA 
dimer within the MoMLV RNP. Specifically, I wished to test the hypothesis that 
Gag-Pol and the gRNA dimer are incorporated into MoMLV RNPs by distinct 
“counting” mechanisms. To test this hypothesis, I produced MoMLV particles 
containing variable proportions of Gag and Gag-Pol and variable proportions of 
Gag and gRNAs or Ψ/DLSʼs. By manipulating the proportions of these molecules, 
I showed that Gag-Pol incorporation into MoMLV particles was stochastic, 
whereas incorporation of gRNAs was saturable. 
 In Chapter IV, I summarize the conclusions of Chapters II and III, present 
additional preliminary data, and discuss potential future experimental directions 
based on the findings presented in this dissertation. Finally, I discuss the 
implications of altering the molecular proportions of the retroviral RNP 




Chapter II  
 
Moloney murine leukemia virus genomic RNA packaged  




The current model for MoMLV genomic RNA (gRNA) packaging predicts 
that of the thousands of Gag proteins in a budding virion, only a small number 
(≤1%) may be necessary to recruit gRNA. Here, we examined the threshold limits 
of functional Gag required to package gRNA using wild-type (WT) and packaging 
deficient mutant nucleocapsid (NC) phenotypically mixed virions. Although gRNA 
packaging was severely diminished for the NC mutant, the residual encapsidated 
RNA dimer displayed motility on gels, thermostability, and integrity that was 
indistinguishable from that of WT. In phenotypically mixed virions, gRNA 
encapsidation recovered to within approximately two-fold of WT levels when the 
amount of WT NC was 5-10% of the total. Our results demonstrate that NC’s 
roles in gRNA dimerization and packaging are genetically separable. Additionally, 
MoMLV gRNA packaging does not require 100% WT NC, but the amount of 
functional NC required is greater than the predicted minimum. 
Introduction 
 
The retroviral Gag polyprotein is responsible for directing virus assembly 
and genomic RNA (gRNA) packaging (reviewed in (25, 37, 75, 110)). The full-
length Moloney murine leukemia virus (MoMLV) Gag polyprotein, termed 
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Pr65Gag, consists of four structural domains: matrix (p15 MA), p12, capsid (p30 
CA), and nucleocapsid (p10 NC). The NC domain of Pr65Gag is responsible for 
specific recruitment and packaging of MoMLV gRNA into newly forming virions 
(6, 111). MoMLV NC contains a single conserved ”zinc knuckle” domain (C-X2-C-
X4-H-X4-C; C=Cys, H=His, X=variable) (51), which is required for NC-gRNA 
interactions (Fig II-1A). Mutations within this domain disrupt viral assembly, 
gRNA packaging, and infectivity (43, 46, 83, 92, 111). 
The region of MoMLV gRNA bound by NC during packaging is contained 
within the 5’-untranslated region (UTR) and is known as Ψ (Psi) for “packaging 
signal” (80). Mutations or deletions of MoMLV Ψ result in gRNAs that are poorly 
packaged (34, 80, 93). MoMLV gRNAs are packaged as dimers that are coupled 
in a dimer linkage structure (DLS). The DLS is defined by sequences that overlap 
with Ψ, and studies have demonstrated that the two regions, and therefore gRNA 
dimerization and packaging, are intimately linked (reviewed in (25)). The Ψ/DLS 
region contains several conserved UCUG and related Py-Py-Py-G 
(Py=pyrimidine) high-affinity NC binding sites (26, 29). Within the MoMLV RNA 
monomer, these high-affinity binding sites are sequestered by base pairing 
interactions; however, upon dimerization these sites are exposed and competent 
for NC binding (26, 40, 86, 87). This molecular “switch” provides a mechanism for 
the preferential recruitment of MoMLV gRNA dimers into newly forming virions. 
The MoMLV NC zinc knuckle contains a conserved tryptophan (Trp 35) 
that plays a direct role in mediating NC-gRNA interactions. Trp 35 coordinates 
the binding of NC to its conserved high-affinity UCUG binding sites on the gRNA 
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dimer by defining a pocket into which the guanosine residue fits and binds with 
high affinity (26, 29). As shown in Fig II-1B, the indole functional group of Trp 35 
defines one side of the guanosine binding pocket by aligning parallel with the 
planar pyrimidine-imidazole ring system of guanosine 309 (which is in a UCUG 
motif from MoMLV nucleotides 306-309). Similar guanosine binding pockets 
defined by conserved Trp and Phe residues are also present on both of the HIV-
1 NC zinc knuckles (89, 126, 127, 130, 131). Disruption of the MoMLV guanosine 
binding pocket by mutating Trp 35 to Ser or Gly results in severe packaging 
defects (46, 83).   
 The number of high-affinity NC binding sites in both the MoMLV RNA 
monomer and gRNA dimer has been revealed by in vitro binding analysis. When 
in vitro transcribed RNAs consisting of nucleotides 147-623 of the MoMLV 5’-
UTR are dimerized, approximately one dozen high-affinity binding sites are 
available for binding of recombinant NC. In contrast, when mutations in the in 
vitro transcribed RNAs are introduced that inhibit dimerization, only one or two 
high-affinity binding sites are available on the MoMLV monomer for recombinant 
NC binding (86).This observation predicts that of the putative thousands of 
copies of Pr65Gag in an MoMLV virion (by analogy to HIV; (16)), only about a 
dozen (or ≤1%) may need to engage in high-affinity NC-gRNA interactions to 
promote packaging. 
To test the hypothesis that only a small number (≤1%) of gRNA binding 
competent Pr65Gag molecules may be required for MoMLV gRNA packaging 






Figure II-1: Interactions between the MoMLV NC “zinc knuckle” domain and 
gRNA high affinity binding sites. (A) Schematic representation of the zinc 
knuckle of MoMLV NC from amino acids 21 to 44. Trp 35 (W) is shown in bold. 
(B) The guanosine binding site of the MoMLV zinc knuckle is defined on one side 
by the side chain of Trp 35 and the other by the side chains of Ala 36, Ala 27, 
and Leu 21. The zinc atom is shown coordinated by the cysteine (yellow) and 
histidine (blue) side chains of the conserved “CCHC” zinc knuckle. Depicted here 
is guanosine (Gua) 309, which is in a high affinity UCUG binding site from 
MoMLV nucleotides 306-309. 
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glycine substitution at amino acid position 35 within the zinc knuckle of NC was 
co-expressed with WT NC to generate phenotypically mixed virions containing 
both WT and W35G NCs. Single cycle replication properties and the amounts 
and properties of gRNA packaging for mixed virions containing limiting amounts 
of WT NC were examined directly. 
Results 
 
W35G NC mutant virus production 
 
 In order to determine the threshold levels of NC required for gRNA 
packaging, a MoMLV zinc knuckle mutant was first constructed and 
characterized. A single mutation of Trp 35 within the zinc knuckle of NC was 
selected based on (i) previous studies demonstrating that mutations of this 
residue do not affect MoMLV assembly but lead to significant reductions in gRNA 
packaging (46, 83), and (ii) in vitro structural and biophysical studies showing 
that this residue contributes to the high-affinity gRNA binding (26).  
To examine the impact of the Trp 35 NC mutation on virus production, 
293T-derived ET cells (106) were transfected with WT and W35G mutant proviral 
plasmids (pGPP(WT) and pGPP(W35G), Fig II-2A), and virus production was 
quantified by a reverse transcriptase (RT) assay (Fig II-2B). Media harvested 
from cells transfected with the W35G mutant proviral plasmid exhibited an 
approximate two-fold reduction in RT activity per volume compared to those 
transfected with the WT proviral plasmid (Fig II-2B).  
To determine the cause of this decrease in RT release into the medium, 




Figure II-2: Virus release of W35G NC mutant MoMLV. (A) Diagram of MoMLV 
gag-pol-puro (GPP) vectors. pNCA is the parental infectious MoMLV proviral 
clone from which pGPP(WT) and pGPP(W35G) were derived. pGPP(WT) 
contains an SV40 driven puroR cassette in the place of env. pGPP(W35G) 
contains a single amino acid substitution (W35G) in the NC of pGPP(WT). (B) RT 
activities of media from cells transfected with pGPP(WT) and pGPP(W35G). 
Quantification by phosphorimager analysis of RT activity upon endpoint dilution 
for the W35G mutant is shown relative to WT, which is set to 100%. Data 
represented are the mean of 6 independent experiments. Error bars indicate the 
standard error of the means. (C) Western blots of virus lysates and (D) lysates of 
ET cells transfected with pGPP(WT) and pGPP(W35G). (E) Western blots of 
virus lysates and (D) lysates of 3T3 cells stably transduced with pGPP(WT) and 
pGPP(W35G). W35G #1 and #2 represent two distinct clonal 3T3 cell lines stably 
transduced with pGPP(W35G). 
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by western blot analysis (Fig II-2C and D). Viral protein lysates revealed an 
approximate two-fold reduction in total Gag (Pr65Gag and p30 CA) released from 
cells for the W35G mutant relative to WT (Fig II-2C, lanes 1 and 2). Conversely, 
western blot analysis of cellular lysates revealed an approximate two-fold 
increase in total Gag retained in cells for the W35G mutant (Fig II-2D, lanes 1 
and 2). This result suggests that introducing the W35G mutation into NC resulted 
in a modest (approximately two-fold) reduction in virus release from ET cells. 
In contrast, although minor differences in Pr65Gag amounts were revealed 
by western blot analysis, no difference in the pattern of proteolytic processing 
was observed between WT and the W35G mutant (Fig II-2C and D). These 
results are consistent with previous studies (46, 83), and suggest that the W35G 
mutation does not alter Gag processing and has little effect on virus release in 
ET cells 
Virus production of the W35G mutant was also examined in NIH 3T3 cells. 
3T3 cells were stably transduced with pGPP(WT) and pGPP(W35G) and viral 
and cell-associated protein lysates were compared by western blot analysis (Fig 
II-2E and F). In contrast to virus production observed in ET cells, the W35G 
mutant exhibited a severe release defect relative to WT in 3T3 cells (Fig II-2E), 
despite similar protein expression levels in cells (Fig II-2F). These results 
suggest that there are cell type specific differences in the ability of W35G NC to 
support virus assembly. Transfected ET cells were used for virus production in 
subsequent experiments below. 




 To determine the gRNA packaging phenotype of the W35G mutant, the 
amount of gRNA packaged in virions produced from ET cells transfected with WT 
and W35G proviral plasmids was determined by RNAse protection assay (RPA). 
Viral RNA samples were hybridized to a chimeric riboprobe containing 
sequences complementary to both MoMLV gRNA and 7SL, which is a host RNA 
packaged by MoMLV at levels proportional to virion proteins (99) (Fig II-3A). RNA 
from the same amount of virions, as quantified by RT activity, was loaded in each 
lane, with 7SL serving as an RNA internal control. Quantification of gRNA/7SL 
ratios revealed that gRNA packaging levels in the W35G mutant virions were 
approximately 5% of WT levels (Fig II-3B), in agreement with previous reports 
(46, 83). 
Next, the impact of the W35G mutation on gRNA dimerization was 
examined by non-denaturing northern blotting (Fig II-3C). The results showed 
that nondenatured W35G mutant and WT virus gRNAs had indistinguishable gel 
mobilities (Fig II-3C, lanes 1 and 8), i.e., they migrated at the dimer position. 
Furthermore, the thermostability of the dimer linkage for W35G and WT gRNAs 
did not differ significantly (Fig II-3C, lanes 2 to 7 and 9 to 13). Additionally, the 
amount of RNA fragmentation, a characteristic typical of retroviral gRNAs (22, 
60), was no greater for the W35G mutant than for the WT (Fig 3C). 
WT and W35G NC incorporation into phenotypically mixed virions 
 
 The above studies demonstrated that the W35G mutation inhibits gRNA 





Figure II-3: W35G NC mutant gRNA. (A) RPA of viral RNA harvested from cells 
transfected with pGPP(WT) and pGPP(W35G). Mobilities of gRNA and 7SL 
products are indicated on the right. Lane markers include: undigested probe [P] 
(pAO993-11), RNA size markers [M], and digested probe-alone control [C]. Gel 
loading was normalized for virion content by RT activity. (B) Quantification of 
gRNA packaging shown in (A) by phosphorimager analysis is presented as ratios 
of gRNA/7SL, with the WT level set to 100%. Quantification represents the mean 
of four independent experiments and the error bars indicate the standard error of 
the means. (C) Non-denaturing northern blot of viral RNA harvested from cells 
transfected with pGPP(WT) and pGPP(W35G). RNAs were subjected to the 
indicated temperature for 10 min prior to electophoresis. Migrations of the gRNA 
dimer and denatured gRNA monomer are indicated. The sample lanes containing 
RNAs isolated from the W35G virus (lanes 8 to 13) were image-adjusted to WT-




cells, gRNA dimerization, gRNA integrity, or proteolytic processing of Gag. The 
mutation was therefore considered suitable for gRNA packaging studies using 
phenotypically mixed virions, which were prepared by co-expressing WT and 
W35G proviral expression plasmids at various input ratios.  
 As observed above, virion release for the W35G mutant alone was 
approximately two-fold lower then for WT (Fig II-4A, lanes 1 and 2). With virions 
produced from co-transfection of various input ratios of WT and W35G mutant 
plasmids, release recovered to near WT levels as the amount of input WT NC 
plasmid increased from 1% to 50% (Fig II-4A, lanes 3 to 10). Western blot 
analysis confirmed both the modest release defect of the W35G mutant alone 
(Fig II-4B, lanes 1 and 2) and the recovery to near WT levels of virus release as 
the amount of input WT NC plasmid increased from 1% to 50% (Fig II-4B, lanes 
3 to 10).  
 Although these experiments examined virion production when W35G and 
wild type Gag were co-expressed, they did not directly address whether or not 
protein mixtures co-assembled to form individual virions. To determine if there 
was a bias in the incorporation of WT or W35G mutant NC into the phenotypically 
mixed virions, the assumption that virions contained ratios of WT and W35G NC 
that matched the stoichiometry of the input proviral expression plasmids was 
then tested. For this assay, packaging-defective MoMLV plasmids containing 
either WT or W35G NCs (called pΔΨMoMLV and pΔΨMoMLV(W35G) 




Figure II-4 : WT and W35G NC phenotypically mixed virion production. (A) 
Quantification of viral release into the culture media and (B) Western blot of 
lysates of virus harvested from media from cells transfected with the indicated 
ratios (W35G/WT) of pGPP(W35G) and pGPP(WT). Values for phenotypically 
mixed virions in (A) are normalized to WT levels, which are set to 100%. Data 
represent the means of at least 5 independent experiments. Error bars indicate 




defective MoMLV plasmid containing a protease-inactivating aspartic acid-to-
serine mutation at amino acid position 32 (pΔΨMoMLV(PR-)) (Fig II-5A). This  
approach for testing co-assembly of co-expressed Gag proteins was designed to 
ensure that any proteolytic processing in newly formed virions was due to the 
incorporation of catalytically active protease associated with either a WT or 
W35G mutant NC-containing polyprotein. 
 Western blotting confirmed that virus harvested from ET cells transfected 
with pΔΨMoMLV(PR-) was defective in the proteolytic processing of Gag (Fig II-
5B, lane 1). Phenotypically mixed virions harvested from cells co-transfected with 
pΔΨMoMLV(PR-) and increasing concentrations of the plasmids pΔΨMoMLV or 
pΔΨMoMLV(W35G) displayed increased Gag processing as the amount of 
protease competent MoMLV increased (Fig II-5B, lanes 2 to 4 and 5 to 7). Even 
at the highest level of WT PR examined here (30%; Fig II-5B lanes 4 and 7)), 
Gag processing was significantly lower than that observed for WT (Fig 2C) 
presumably because the PR point mutant used here associates at random with 
WT PR monomers in mixed virions to generate inactive PR+: PR- heterodimers. 
However, overall, the Gag processing profile at each concentration of protease-
competent MoMLV was the same, regardless of whether the PR+ plasmid 
contained WT or W35G mutant NC (Fig II-5B, lanes 2 to 4 and 5 to 7). These 
results suggest that there was no bias in virion incorporation of either WT or 





Figure II-5: WT and W35G NC incorporation into phenotypically mixed 
virions. (A) Diagram of ΔΨMoMLV vectors. pNCA is the parental infectious 
MoMLV proviral clone from which the following vectors were derived. 
pΔΨMoMLV contains a “classic Ψ” deletion (80). pΔΨMoMLV(PR-) and 
pΔΨMoMLV(W35G) contain “classic Ψ” deletions and also contain single amino 
acid substitutions in protease (D32S) and NC (W35G) respectively. (B) Western 
blot of virus lysates of phenotypically mixed virions produced from cells 
transfected with pΔΨMoMLV(PR-) and increasing concentrations of PR+ MoMLV 
(pΔΨMoMLV or pΔΨMoMLV(W35G)). The following three PR-/PR+ ratios were 
utilized: 1/0.01, 1/0.10, and 1/0.30). The plasmid pMΨPuro was included in each 
transfection to serve as gRNA. Full length Pr65Gag and processed p30 CA are 
indicated on the right. 
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individual phenotypically mixed virions matched the input proviral expression 
plasmid ratios. 
gRNA packaging in phenotypically mixed virions 
 
 Having produced phenotypically mixed virions, and performed control 
experiments to examine biases in the co-assembly of WT and W35G mutant 
NCs, the gRNA packaging efficiency of these virions was determined by RPA. 
RNA harvested from phenotypically mixed virons was normalized to RT activity 
and probed with a chimeric riboprobe that recognized both gRNA and 7SL. As 
observed above, quantification of gRNA/7SL ratios showed that gRNA packaging 
levels for the W35G mutant were approximately 5% of WT levels (Fig II-6A and 
B, lanes 1 and 2). With phenotypically mixed virions, gRNA packaging recovered 
to near WT levels as the amount of WT NC increased from 1% to 50% of the 
total NC present (Fig II-6A and B, lanes 3 to 10). When the amount of WT NC 
was approximately 5-10% of the total, gRNA packaging recovered to within two-
fold of WT levels (Fig II-6A and B, lanes 5 to 7).  
Phenotypically mixed virus single-cycle infectivity 
 
 To determine whether packaging efficiency was the only replication defect 
of W35G NC containing virions, replication of phenotypically mixed virions was 
analyzed using a single-cycle infectivity assay. Virions produced from ET cells 
co-transfected with various ratios of pGPP(WT) and pGPP(W35G) mutant 
proviral plasmids were used to infect fresh target cells. Because pGPP 
derivatives contain a puromycin N-acetyltransferase (puroR) gene in place of the 




Figure II-6: gRNA packaging of WT and W35G NC phenotypically mixed 
virions. (A) RPA of viral RNA harvested from cells transfected with the indicated 
ratios (W35G/WT) of pGPP(W35G) and pGPP(WT). gRNA and 7SL bands are 
indicated on the right. Lane markers include: undigested probe [P] (pEG467-10), 
RNA size markers [M], and digested probe-alone control [C]. Gel loading was 
normalized for virion content by RT activity. (B) Quantification of gRNA 
packaging shown in (A) by phosphorimager analysis is presented as ratios of 
gRNA/7SL, with the WT level set to 100%. Quantification represents the mean of 
at least three independent experiments and the error bars indicate the standard 
error of the means. 
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forming units per milliliter (CFU/mL) could be determined (Fig II-7). The titer of 
the W35G mutant, when normalized for virion abundance, was decreased 
approximately 1000-fold relative to WT (Fig II-7A, lanes 1 and 2). For the 
phenotypically mixed virions, titer recovered as the amount of WT NC increased 
from 1% to 50% of the total NC and plateaued at approximately half of WT levels 
(Fig II-7A, lanes 3 to 10).  
 To determine what portion of the decrease in viral titer was due to gRNA 
packaging defects, the results were also normalized to input gRNA levels as 
measured by RPA (Fig II-6). In this case, the titer for virions containing 100% 
W35G mutant was approximately 100-fold lower than WT (Fig II-7B, lanes 1 and 
2). Again, titer recovered to only half of WT levels as the amount of WT NC 
increased from 1% to 50% of the total NC (Fig II-7B, lanes 3 to 10). 
Analysis of reverse transcription error rates of phenotypically mixed virus 
 The above results suggested that in addition to inhibiting gRNA 
packaging, the W35G mutation negatively impacted other NC functions early in 
the infection process. To test if errors in reverse transcription contributed to the 
decrease in proviral titer of the W35G mutant, a lacZ inactivation assay was 
performed (13, 105, 106). In these experiments, virions comprised of phenotypic 
mixtures of WT and W35G Gag, and which packaged a dual marker vector 
expressing both lacZ and puroR, were generated as described in Materials and 
Methods. These were used to infect fresh target cells, and provirus-containing 
puromycin resistant colonies were stained with X-Gal and counted (Fig II-8). 






 Figure II-7: Infectivity of WT and W35G NC pheotypically mixed virions. Titer 
of virus produced from cells transfected with the indicated ratios (W35G/WT) of 
pGPP(W35G) and pGPP(WT). Data was initially collected as puromycin-resistant 
colony forming units per mL (CFU/mL) and is presented in (A) normalized to 
virion RT activity (Fig 4) and (B) to virion gRNA packaging levels (Fig 6). 
Quantification represents the mean of at least three independent infections (of 
duplicate plates) with virons produced from at least three independent 
transfections. Error bars indicate the standard error of the means. 
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as the amount of WT NC decreased to 1% of the total NC (Fig II-8B, lanes 1 to 
5). Additionally, the titer of the W35G mutant alone was decreased approximately 
1000-fold relative to WT alone (Fig II-8B, lanes 1 and 7). 
 Consistent with previous studies (13, 105), the lacZ inactivation rate, 
represented as the percent of white colonies relative to the total number of 
colonies (% white colonies), for WT virus was approximately 10% (Fig II-8C, lane 
1), and lacZ inactivation from control phenotypically mixed virions containing 95% 
RNAse H (RH) mutant and 5% WT RH increased approximately two-fold relative 
to WT only (Fig II-8C, lane 1 and 8).In the experimental samples, lacZ 
inactivation rates remained relatively unchanged for virions containing as little as 
10% WT NC (Fig II-8C). However, with phenotypically mixed virions containing 
lower ratios of WT to W35G NC, the lacZ inactivation rates increased steeply (Fig 
II-8C, lanes 2 to 5). The lacZ inactivation rate of W35G mutant virus alone was 
100%, as no blue colonies (out of 58 total colonies across five independent 
infections) were observed (Fig II-8C, lane 6). Taken together, these results 
suggest that in addition to decreases in gRNA packaging, errors in reverse 
transcription contributed to, but do not fully account for, decreases in provirus 





Figure II-8: Reverse transcription error rates of WT and W35G NC 
phenotypically mixed virions. (A) Schematic overview of the lacZ inactivation 
assay described in the text. (B) Titer of virus (CFU/mL) produced from cells 
transfected with the indicated ratios of pΔΨMoMLV, pΔΨMoMLV(W35G), or 
pMoMLVΨ-DNAP+RH- (RH-). (C) lacZ inactivation (% white colonies) of virus 
produced from cells transfected with the indicated ratios of the above plasmids. 
Quantification in (B) and (C) represents the mean of at least four independent 
infections (of duplicate plates) with virus produced from three independent 





The current model of gRNA packaging for MoMLV, based on in vitro 
binding studies, predicts that only a small number of functional Gag molecules 
(possibly only 12, or ≤1% of all Gag molecules) are required to engage in high-
affinity interactions with gRNA to initiate retroviral assembly. This packaging 
model is consistent with fluorescence microscopy studies in cells, which indicate 
that the HIV dimeric RNA genome is trafficked to plasma membrane assembly 
sites by a small number (a dozen or fewer) of HIV-1 Gag proteins (61). The goal 
of the present study was to test predictions derived from the in vitro studies in a 
cell culture system and examine the threshold limits of MoMLV Gag required to 
package gRNA. 
 Phenotypically mixed virions containing WT and packaging deficient 
W35G mutant NCs were found to package near WT levels of gRNA when 
amounts of packaging-competent NC represented half of the total. When 
packaging-competent Gag was reduced to 5-10% of the total, virions showed a 
modest packaging defect (approximately two-fold). Similar results obtained for 
HIV-1 (120) suggest that this phenotype is conserved among retroviruses.  
 The results described here suggest that the threshold limits of MoMLV 
Gag required to packaged gRNA are greater than what the above packaging 
model predicts. A possible explanation for the modest defect observed at 
threshold levels of functional Gag is that the initially formed Gag NC-gRNA 
complex may be structurally compromised, to some extent, by the presence of 
mutant Gag proteins. In other words, proper gRNA packaging may require the 
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occupation of all high-affinity NC binding sites by WT NC, and the presence of 
even a small amount of mutant-NC containing Gag might be sufficient to disrupt 
proper packaging.  Gag-Gag interactions mediated by the wild type CA domain 
could help recruit mutant Gag proteins to the packaging signal, thereby 
facilitating the incorporation of mutant Gag molecules despite the predicted 
reduction in NC:RNA affinity. 
 Additional work here demonstrated a genetic separation between gRNA 
packaging and other replication functions for the W35G mutant. For example, our 
results showed that the W35G mutation did not impair gRNA dimer formation or 
gRNA integrity. gRNA dimer formation is dependent on the ability of NC to lower 
the energy barrier required to disrupt and re-form favorable base pairing 
interactions within gRNA dimers (41, 108, 112). In addition, the coating of gRNA 
with one NC molecule every 5 to 8 nucleotides (71) is thought to be important to 
protect the gRNA from nuclease degradation both in cells (reviewed in (135)) and 
most relevant for our results, in virions (60, 64). In work describe here, the W35G 
mutant retained the ability to both protect the gRNA in virions from 
endoribonuclease digestion and promote the formation of gRNA dimers.  
 An additional phenotype of the W35G mutant described here was a 
modest but reproducible release defect in human 293T-derived ET cells. This 
corresponded to an increase in cell-associated viral protein, suggesting that Gag 
was retained in the cells. This phenotype has been observed in human cells with 
other NC mutants that have been shown to impair MoMLV assembly (92). 
Defects in virus release may be due to disruptions in NC-gRNA interactions in 
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higher order Gag oligomers that are responsible for forming the structure of 
newly forming virions (reviewed in (110)). Here, virus release from ET cells 
recovered when the amount of WT Gag in phenotypically mixed virions 
approached half of the total Gag, suggesting that the NC-gRNA interactions 
required to form higher order Gag oligomers do not require a full complement of 
packaging competent Gag. 
 Experiments described here were performed in human cells based on our 
observation that W35G virus release was severely attenuated in murine cells. 
This result correlates with previous studies where MoMLV NC Trp 35 mutants 
were shown to quickly revert to WT upon passaging in murine cells (46, 83).  
 Our results demonstrated that the W35G mutant was approximately 100-
fold less infectious than WT in a single cycle infectivity assay, when normalized 
for packaged gRNA levels. Interestingly, in phenotypically mixed virions, 
infectivity did not recover to WT-like levels at the same W35G:WT NC ratio as 
virus release or gRNA packaging, suggesting that a full complement of WT NC 
may be required for productive early infection events.  
 NC is known to have many functions in the early steps of retroviral 
replication which are dependent on its nucleic acid chaperone activity (reviewed 
in (27, 71, 72, 135). For example, aberrant reverse transcription products result 
when NC’s chaperone functions are impaired by mutating zinc-coordinating 
residues (44, 45), and Trp 35 mutant MoMLV NC has been shown to decrease 
reverse transcription through regions of RNA secondary structure (146). 
Consistent with the notion that disrupting NC’s chaperones function results in 
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aberrant reverse transcription products, we observed defects in reverse 
transcription for the W35G mutant as measured by a genetic marker inactivation 
assay for phenotypiclally mixed virions containing ≥95% W35G. Although not 
tested explicitly, the observation of large decreases in titer at low W35G 
concentrations suggests that additional defects, such as in reverse transcription 
initiation, may have contributed to the defects in W35G virion infectivity. 
Published work showing that primer tRNA placement and annealing are 
dependent on retroviral NC’s chaperone function are consistent with this notion 
(72). 
In summary, the work presented here showed that MoMLV zinc knuckle 
mutant W35G and WT NC Gag molecules readily co-assembled, and that the 
resulting phenotypically mixed virions encapsidated roughly half as much gRNA 
as wild type particles when a 5-10% threshold of WT NC was reached. These 
studies also demonstrated that authentic dimerization of MoMLV gRNAs and the 
maintenance of gRNA integrity were independent of the chaperone functions 
provided by the MoMLV NC zinc knuckle. Nonetheless, replication defects for 
phenotypically mixed virions were greater than those predicted by gRNA 
packaging levels, further underscoring the myriad roles of NC in retroviral 
replication. 
Materials and Methods 
 
Cells and Transfectons 
ET cells, which are 293T cells that constitutively expresses murine 
ecotropic envelope, and ET-pLacPuro cells, which are ET cells that constitutively 
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express an MoMLV vector containing both a LTR promoter driven lacZ gene and 
a simian virus 40 (SV40) promoter driven pruomycin N-acetltransferase (puroR) 
gene in place of the viral genes (106), were maintained in Dulbecco’s modified 
Eagles’s medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum 
(Gemini), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen). 
D17/pJET cells, a canine osteosarcoma cell line that constitutively expresses 
murine ecotropic receptor (98), and NIH 3T3 cells were maintained in DMEM 
supplemented with 10% bovine serum (Invitrogen), 100U/mL penicillin, and 100 
µg/mL streptomycin (Invitrogen). Both ET and D17/pJET cells were grown at 
37°C with 5% CO2 in a humidified incubator. Transfections were carried out using 
polyethlenimine (PEI) as described previously (64).  
Plasmids 
The MoMLV-based gag-pol-puro plasmid, pGPP(WT) (aka pSRK876-15), 
contains an intact provirus modified by the replacement of the env open reading 
frame with a puroR driven by a SV40 promoter (Fig II-2A) (106). The W35G NC 
mutation in pGPP(W35G) (aka pEG479-1) was generated by overlap extension 
PCR, sequenced, and used to replace the corresponding portion of pGPP(WT) 
(Fig II-2A). 
The “classic Ψ” deletion (Δ215-568) (80) in pΔΨMoMLV (aka pAO147-2) 
was generated by overlap extension PCR, sequenced, and used to replace the 
corresponding portion of pNCA (24) (Fig 5A). A restriction fragment 
encompassing the W35G mutation in NC of pGPP(W35G) replaced the 
corresponding portion of pΔΨMoMLV to generate pΔΨMoMLV(W35G) (aka 
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pSFJ93-1) (Fig II-5A). For pΔΨMoMLV(PR-) (aka pSFJ229-1), site directed 
mutagenesis was performed using the QuikChange II Site-Directed Mutagenesis 
Kit (Stratagene) to introduce an aspartic acid-to-serine mutation at amino acid 
position 32 of MoMLV protease (PR) in pΔΨMoMLV, which sequencing 
confirmed (Fig II-5A). Construction of the MoMLV packaging vector pMΨPuro 
(aka pAM86-5) and the RNAse H mutant (D524N) plasmid pMoMLVΨ-DNAP+RH- 
(aka pTW76-3) were described previously (13, 68). 
The riboprobe templates were derivatives of pBSII SK(+) (Stratagene) that 
contained PCR fragments inserted into the EcoRV site. The PCR insert in 
pAO993-11 includes complementarity to portions of both MoMLV 5’-UTR 
(nucleotides(nt) 55-255) and 100 nt of 7SL RNA (99). The insert in pEG467-10, 
which was generated by PCR from pAO993-11, also included complementarity to 
portions of both MoMLV 5’-UTR (nt 55-214) and 100 nt of 7SL RNA (38). 
Virus Isolation 
Virus was isolated from tissue culture supernatants harvested at 48 h post 
transfection by centrifugation (64). For western blotting, the viral pellets were 
resuspended in RIPA lysis buffer (1% NP40, 0.1% sodium dodecyl sulfate, 0.5% 
sodium deoxycholate, 150 mM Nacl, 50 mM Tris [pH7.5]) supplemented with 1X 
protease inhibitor cocktail (PIC) tablet (Roche) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF). Viral protein lysates were stored at -20°C. For RNAse 
protections assays, viral pellets were resuspended in TRIzol reagent 
(Invitrogen) and stored at -80°C. For non-denaturing northern blots, RNA was 
isolated from viral pellets using proteinase K-based extraction (35). Virus was 
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quantified using an exogenous reverse transcriptase (RT) assay (38) based on a 
previously described protocol (134). 
Western Blotting 
Total cell protein was harvested in RIPA lysis buffer supplemented with 1X 
PIC tablet (Roche) and 1 mM PMSF. Cells were first lysed on ice for 30 min in 
RIPA buffer and then cleared by centrifugation at 13,000 rpm for 20 min at 4°C. 
Virus lysates were prepared as described above.  
Cell and virus lysates were resolved by SDS-PAGE and transferred to 
polyvinylidene fluoride (PVDF; Bio-Rad) membranes overnight using a Mini-
PROTEAN 3 Cell transfer apparatus (Bio-Rad). Membranes were blocked in 
1% nonfat dried milk in TBS (50 mM Tris [pH7.5], 150 mM NaCl) for 1 h at room 
temperature. After blocking, membranes were incubated with primary antibodies 
diluted in 1% nonfat dried milk in TBS containing 0.1% Tween-20 (TBS-T), for 1 h 
at room temperature. The rat mAb against MoMLV p30 CA was derived from 
hybridoma supernatants (from Bruce Chesebro: ATCC clone R187) and diluted 
1:600. The beta-actin mAb (Ambion: AM4302) was diluted 1:5,000.  
Secondary antibodies were diluted in 1% nonfat dried milk in TBS-T and 
incubated for 1 h at room temperature. The following dye-conjugated secondary 
antibodies were utilized at a 1:7,500 dilution: goat anti-rat IRDye 800CW and 
goat anti-mouse IRDye 680 (Li-Cor Biosciences). After incubation in both 
primary and secondary antibodies, the membranes were washed 3 times with 
TBS-T. A final wash in TBS was performed before proteins were detected and 
quantified using the Li-Cor Odyssey system (Li-Cor Biosciences). 
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RNAse Protection Assay (RPA) 
 To produce riboprobes, pAO993-11 and pEG467-10 (see above) were 
linearized with HindIII and in vitro transcribed using T3 RNA polymerase 
(Promega) and [α-32P]-rCTP (Perkin-Elmer). pAO993-11 protects 200 nt of 
MoMLV gRNA and 100 nt of 7SL RNA while pEG467-10 protects 163 nt of 
MoMLV gRNA and 100 nt of 7SL RNA respectively. Hybridization of riboprobes 
with sample RNA, RNAse digestion, and resolution was carried out as described 
previously (86). 
Non-Denaturing northern blot 
Non-denaturing northern blot analysis of viral RNAs isolated by the 
proteinase-K-based extraction method (see above) was carried out as described 
previously (86).  
Infections  
D17/pJET cells were infected in 35 mm dishes for 4 h in the presence of 
hexadimethrine bromide (Polybrene; Sigma). Virus-containing media was then 
removed and cells were transferred to 10 cm dishes. 48 h post infection, media 
containing 2 µg/mL puromycin was added and after 12 days of selection, 
colonies were stained with crystal violet for counting. Infectious units are 
represented as colony forming units per milliliter (CFU/mL). 
lacZ inactivation assay 
 Virions produced from ET-pLacPuro cells co-transfected with various 
ratios of pΔΨMoMLV and pΔΨMoMLV(W35G) or pMoMLVΨ-DNAP+RH- mutant 
proviral plasmids were used to infect D17/pJET cells as described above. After 
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selection, colonies were stained with 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) and counted. 
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Chapter III  
 
 The molecular proportions of the Moloney murine leukemia virus Gag-Pol 
polyprotein and genomic RNA are determined by disparate mechanisms  
 
Abstract 
 The Moloney murine leukemia virus ribonucleoprotein (RNP) complex is 
composed of a 20:1 mixture of the viral Gag and Gag-Pol polyproteins plus a 
single genomic RNA (gRNA) dimer. The mechanism that regulates the 
conserved proportions of RNP constituents is unknown. Here, I examined 
whether the proportions of Gag, Gag-Pol, and gRNA in virions are determined by 
sampling, that is, if they reflected expression ratios or intracellular 
concentrations, or more specific recruitment. To this end, I utilized an 
experimental system whereby MoMLV Gag, Gag-Pol, and gRNA, were 
expressed separately, thereby allowing manipulation of the ratios of the two 
polyproteins and gRNA. Upon varying the ratios of Gag and Gag-Pol in MoMLV 
particles, I observed that Gag-Pol incorporation was stochastic and that 
maintenance of the conserved 20:1 Gag:Gag-Pol ratio coincided with maximal 
particle production. An overabundance of Gag-Pol relative to Gag resulted in 
particles that maintained intracellular protein ratios but were defective in particle 
production. In addition, I obtained evidence that MoMLV Gag-Pol may be 
involved in regulating the amount of gRNA packaged into particles but that the 
NC domain of either Gag or Gag-Pol can provide the gRNA packaging function 
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during MoMLV assembly. By manipulating both the ratio of Gag to gRNA and 
that of Gag to Ψ/DLSʼs in MoMLV particles, I tested which of the above described 
mechanisms is responsible for determining the molecular proportion of Gag and 
gRNA. Unlike when Gag-Pol was overexpressed, I observed an upper limit of 
gRNA incorporation and no significant disruption of MoMLV particle production 
when the proportion of Gag to gRNA or Ψ/DLSs was altered. 
Introduction 
 Retroviruses such as Moloney murine leukemia virus (MoMLV) can be 
considered RNP complexes, comprised of proteins and RNA, surrounded by a 
lipid envelope. Within the MoMLV RNP, the Gag and Gag-Pol polyproteins are 
the major and minor viral protein components respectively, whereas the viral 
gRNA is the major RNA component. Assuming that absolute numbers are 
analogous to those in HIV-1, the MoMLV RNP is composed of roughly 2,500 Gag 
molecules, 125 Gag-Pol meoecules, and precisely one gRNA dimer (16). 
 The MoMLV Gag precursor polyprotein is encoded by the gag gene. gag 
is located near the 5ʼ end of the viral genome, immediately upstream of pol, 
which encodes the viral enzymes. MoMLV Pol is not expressed from its own 
mRNA, but is translated as a C-terminal extension of Gag when the gag stop 
codon is readthrough into the pol reading frame (reviewed in (50)). Therefore, the 
resulting Gag-Pol fusion is identical to Gag in its N-terminus.  
 The mechanism of MoMLV gag stop codon readthrough has been 
elucidated (54). Immediately downstream of the gag stop codon is an RNA 
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pseudoknot structure that is responsible for allowing readthrough via termination 
suppression (reviewed in (3)). Recent NMR-based structural studies have 
demonstrated that at physiological pH the pseudoknot adopts a conformation 
permissive for stop codon readthrough in approximately 5% of MoMLV RNAs, 
whereas a non-permissive conformation is observed in the remaining 95% (54). 
These ratios correlate well with the 20:1 Gag:Gag-Pol ratio observed for MoMLV 
(58). 
 The MoMLV Gag polyprotein directs virus assembly and gRNA packaging 
(reviewed in (110)). The nucleocapsid (NC) domain of MoMLV Gag mediates 
protein-RNA interactions that are important for these processes via its conserved 
“zinc knuckle” motif (51). Certain mutations within NC disrupt virus assembly, 
gRNA packaging, and infectivity (43, 46, 59, 83, 92, 111).  
 MoMLV gRNAs are packaged as dimers: they are linked near their 5ʼ ends 
via a dimer linkage structure (DLS) that overlaps with a region known as Ψ (Psi) 
for “packaging signal”. gRNA dimerization and packaging are physically and 
functionally linked (reviewed in (25)), and mutations or deletions of the Ψ/DLS 
region result in gRNA packaging defects (34, 80, 93). Like Gag, the MoMLV Gag-
Pol polyprotein contains an NC domain. It is unknown if the RNA binding 
interactions of the NC protein in the context of Gag-Pol differ from those in Gag. 
 The MoMLV Gag-Pol polyprotein is thought to be incorporated into 
assembling virions via capsid (CA):CA interactions between the CA domains of 
Gag and of Gag-Pol respectively, in a manner similar to that observed for HIV-1 
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(56, 128). Retroviral Gag and Gag-Pol interactions, which are believed to occur 
subsequent to initial NC-RNA mediated Gag mulitmerization (66), are believed to 
take place within the cytoplasm (47, 70) and are followed by transport to sites of 
assembly at cell membranes (21, 104, 125). 
 The fact that an MoMLV RNP assembles from thousands of Gag 
molecules – each one containing a zinc knuckle-bearing NC domain with an 
intrinsic ability to form high affinity interactions with gRNA – and that not every 
NC forms high affinity interactions with a Ψ/DLS means that there is an 
asymmetry among Gag molecules within the RNP. Presumably, MoMLV Gag 
molecules are separated into two distinct pools: Gags that participate in high-
affinity gRNA interactions and ones that do not (59, 86). Neither the “counting” 
mechanism that regulates the single-dimer packaging specificity of gRNA nor the 
mechanism that segregates the two pools of MoMLV Gag is known.  
 An additional asymmetry exists between Gag and Gag-Pol molecules 
within the RNP, since each of the thousands of Gag molecules contains a CA 
domain with an intrinsic ability to interact with Gag-Pol. That the “counting” 
mechanism that regulates the copy number of Gag-Pol packaged into RNPs is 
manifested by gene expression levels is suggested by the observation that the 
20:1 Gag:Gag-Pol copy number in retroviral RNPs (16) matches the 20:1 
Gag:Gag-Pol expression ratio in cells (54, 58). In other words, this correlation 
suggests that MoMLV Gag-Pol incorporation is stochastic and that incorporation 
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into virions is the result of “sampling” of intracellular population of Gag-Pol. This 
is in contrast to gRNA incorporation, which is highly specific. 
 The goal of the present study was to test the hypothesis that the ratio of 
Gag to Gag-Pol, and of Gag to gRNA in MoMLV particles is determined by 
intracellular expression ratios. In order to manipulate the ratios of Gag and Gag-
Pol in the MoMLV RNP, an experimental complementation system was 
established whereby the intracellular expression of the two proteins was unlinked 
by placing each gene on a separate expression construct. Separating the 
expression of Gag and Gag-Pol allowed the ratio of the two proteins to be 
manipulated experimentally. Using this system, the stoichiometry of Gag-Pol in 
MoMLV particles could be determined. The impact of the manipulation of 
Gag:Gag-Pol ratios on MoMLV production, gRNA packaging, and infectivity was 
then examined. Furthermore, separating the expression of Gag and Gag-Pol 
provided a system to test whether or not the NC domain of Gag-Pol contributes 
to gRNA packaging. 
 Two strategies were employed to manipulate the copy number of gRNA 
within the MoMLV RNP. First, a gRNA overexpression system was used to 
manipulate the intracellular ratio of Gag and gRNA. Second, the ratio of 





MoMLV particle production and incorporation of Gag-Pol  
 In order to test the hypothesis that the ratio of Gag and Gag-Pol in MoMLV 
particles is determined by intracellular expression ratios, an experimental system 
was designed that allowed Gag and Gag-Pol quantification. This system utilized 
MoMLV helper plasmids that contained protease (PR)-inactivating aspartic acid-
to-serine (D32S) mutations (Fig III-1). Use of the PRD32S helpers was designed to 
prevent the proteolytic processing of Gag and Gag-Pol in newly assembled 
particles, thereby allowing visualization of intact polyproteins by western blotting. 
The PRD32S helper constructs provided all the MoMLV proteins in trans for the 
assembly of virus-like particles containing the MoMLV vector pMΨPuro (Fig III-1).  
 To confirm that PR was inactivated by this mutation, MoMLV particles 
were produced by co-transfection of 293T-derived ET cells (106) with pΨ-
MLV(PRD32S) and pMΨPuro, and protein lysates of the resulting MoMLV particles 
were examined by western blot analysis (Fig III-2A). The results confirmed the 
absence of detectable proteolytic processing of Gag and Gag-Pol for the PRD32S 
mutant, since no Pr65 Gag cleavage products were observed under these 
conditions (Fig III-2A). Furthermore, use of the PRD32S mutant allowed resolution 
of full-length Pr180 Gag-Pol (Fig III-2A). Quantification of the amounts of protein 
shown in Fig III-2A revealed that ~6% of total Gag (Pr65 Gag + Pr180 Gag-Pol) 
was comprised of PR180 Gag-Pol. This result is consistent with reported MoMLV 
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Figure III-1: Structure of MoMLV proviral clones. Diagram of MoMLV 
helper constructs used in the experiments described here. pNCA is the 
parental WT MoMLV clone from which all other constructs were 
derived. The MoMLV helpers contain a Ψ deletion from nucleotides 
215-368. Gag/Gag-Pol helpers contain all the viral genes including gag, 
pol, and env. They include pΨ-MLV and pΨ-MLV-derived constructs that 
contain the indicated single amino acid substitutions in protease (D32S) 
and NC (W35G). The Gagonly helpers contain deletions of pol and env 
and include constructs containing both WT and W35G mutant NCs. 
Gag-Polonly helpers are env deleted and contain a mutation that 
eliminates the Gag stop-codon. They include pΨ-MLV-Gag-Polonly and 
pΨ-MLV-Gag-Polonly-derived constructs that contain the indicated D32S 
and W35G point mutations. The MoMLV vector pMΨPuro contains an 




Figure III-2: MoMLV particle production. (A) Western blot of virus 
lysates and (B) cell lysates of ET cells transfected with the indicated 
MoMLV helpers. The MoMLV vector pMΨPuro was included in all 
transfections here to serve as gRNA. 
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gag stop codon readthrough frequencies that result in a 20:1 Gag:Gag-Pol 
expression ratio (54, 58). 
 Consistent with previous studies (122), transfection of ET cells with an 
MoMLV helper that produces only the Gag polyprotein, in this case pΨ-MLV-
Gagonly (Fig III-1), resulted in efficient particle production (Fig III-2A, lane 2). 
Specifically, virus production remained approximately 20% as high for cells 
transfected with pΨ-MLV-Gagonly as with the helper pΨ-MLV(PRD32S) (Fig III-2A, 
lanes 1 and 2). Cell-associated proteins of cells transfected with these helpers 
were also compared by western blot analysis (Fig III-2B), and reveal an 
approximately five-fold decrease in cell-associated Gag for pΨ-MLV-Gagonly 
relative to pΨ-MLV(PRD32S) (Fig III-2B, lanes 1 and 2). These results suggest that 
differences in Gag expression between pΨ-MLV-Gagonly and pΨ-MLV(PRD32S)  
helper constructs largely explain the observed decrease in virus production.   
 Also consistent with previous studies (33), transfection of ET cells with an 
MoMLV helper that produces only the Gag-Pol polyprotein, in this case pΨ-MLV-
Gag-Polonly(PRD32S) (Fig III-1), resulted in drastic reductions in particle production, 
since only small amounts of Pr180 Gag-Pol (~1% relative to Pr65 Gag from pΨ-
MLV-Gagonly) were observed in MoMLV protein lysates (Fig III-2A, lanes 2 and 3, 
and Fig III-3A, lanes 1 and 2). 
 To examine the impact of altered Gag:Gag-Pol polyprotein ratios on 
MoMLV production, pΨ-MLV-Gagonly and pΨ-MLV-Gag-Polonly(PRD32S) were 
transfected into ET cells, either alone or in combination with each other at various 
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Figure III-3: Incorporation of Gag-Pol into MoMLV particles (A) 
Western blot of equal volumes of virus lysates of ET cells either 
transfected alone with the indicated Gagonly or Gag-Polonly helpers 
(lanes 1 and 2) or co-transfected with the indicated ratio of Gagonly/Gag-
Polonly helpers (lanes 3 through 9). (B) Quantification of MoMLV particle 
production shown in (A) is presented as total Gag (Pr65 Gag + Pr180 
Gag-Pol) released into the media and is shown relative to the Gagonly 
alone sample which is set to 100% (C) Quantification of the % Gag-Pol 
in MoMLV particles shown in (A) is presented as % Gag-Pol relative to 
total Gag (Pr65 Gag + Pr180 Gag-Pol). Grey columns represent 
quantification of WB bands and black bars represent the predicted % 
Gag-Pol based on input plasmid ratios. The MoMLV vector pMΨPuro 




molar ratios, in the presence the MoMLV vector pMΨPuro. MoMLV particle 
protein lysates were then examined by western blotting (Fig III-3A). Co-
expression of Gag and Gag-Pol supported efficient particle production across a 
wide range of ratios (Fig III-3A, lanes 3 through 7). However, when Gag-Pol 
represented 50% or greater of the total viral polyproteins co-expressed in cells, 
particle production was attenuated, and particle release decreased approximately 
100 fold or greater relative to particles containing 20:1 “wild-type like” Gag:Gag-
Pol ratios (Fig III-3A and B, lanes 8 and 9).  
 Note that although particle yield decreased as the amount of input Gag-
Pol expression plasmid increased from 1% to 75% of the total Gag expression 
plasmid, the amount of Gag-Pol in particles correspondingly increased (Fig III-3A, 
lanes 3 through 9). Quantification of Gag-Pol in these samples revealed that the 
amount of Gag-Pol observed in particles (actual) closely matched the input 
transfected plasmid amounts (predicted) (Fig III-3C). These results suggest that 
the incorporation of Gag-Pol into MoMLV virions is stochastic across a broad 
range of protein co-expression ratios. 
Impact of MoMLV Gag:Gag-Pol ratio on single-cycle infectivity 
 Next, the impact of altered MoMLV Gag:Gag-Pol polyprotein ratios on 
virus infectivity was determined. Similar to the experiment above, Gag and Gag-
Pol helpers were transfected into ET cells either alone or in combination with 
each other at various input ratios. However, for this assay the Gag-Pol helper pΨ-
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MLV-Gag-Polonly (Fig III-1), which contains a functional PR, was utilized so that 
single-cycle infectivity could be measured. Virus produced in this manner was 
used to infect fresh target cells, and provirus titer, represented as puromycin-
resistant colony forming units per milliliter (CFU/mL), was determined (Fig III-4A). 
The results indicated that titers remained relatively unchanged for virus 
containing 1% to 25% Gag-Pol (Fig III-4A, lanes 3 through 7). In contrast, the 
titers of virus containing 50% Gag-Pol or greater (Fig III-4A, lanes 8 and 9) was 
decreased approximately 100-fold or more relative to the titers of virus with 25% 
or less Gag-Pol. These approximate 100-fold decreases in titer match the 
approximate 100-fold decrease in virus production shown in Fig III-2, thereby 
suggesting that defects in titer reflected defects in virus production and that 
infectivity per virion remained largely unchanged by excess Gag-Pol.   
 Unexpectedly, virus produced from the Gag helper constructs alone (Fig 
 III-4A, lane 1) yielded low but reproducible proviral titers that were greater than 
those observed when cells were infected with media from mock transfected cells 
(Fig III-4A, lane 10). This result was unexpected, since virus that lacks Pol should 
not produce titer in the single-cycle infectivity assay. To determine if the titer 
observed for these MoMLV particles resulted from reverse transcription products, 
a single-cycle infectivity assay was performed in the presence of the reverse 
transcriptase inhibitor 3ʼ-azido-3ʼ-deoxythimidine (AZT) (Fig III-4B). Whereas in 
the absence of AZT a small but reproducible titer (23±6 CFU/mL) was observed 
with virus produced from the helper pΨ-MLV-Gagonly, titer was below the limit of 
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Figure III-4: Impact of MoMLV Gag:Gag-Pol ratio on single-cycle 
infectivity (A) Titer of virus produced from ET cells transfected with the 
indicated Gagonly or Gag-Polonly helpers (lanes 1 and 2) or co-
transfected with the indicated ratio of Gagonly/Gag-Polonly helpers (lanes 
3 thru 9). (B) Titer of virus produced from ET cells transfected with the 
indicated Gagonly helper either in the absence or presence of 200 µM 
AZT. The limit of detection (l.o.d.) for this assay is indicated. 
Quantification is presented as puromycin-resistant colony forming units 
per mL (CFU/mL). Error bars indicate the standard error of the means. 





detection (<1 CFU/mL) in the presence of AZT (Figure III-4B). This suggests that 
the proviral titer observed for pΨ-MLV-Gagonly virus in Fig III-4A and B was the 
result of some form of reverse transcription.  
Impact of MoMLV Gag:Gag-Pol ratio on gRNA packaging 
 One way of quantifying gRNA packaging is determining the ratio of 
gRNA/7SL. 7SL is a host RNA packaged by MoMLV at levels proportional to 
virion proteins (99) and therefore serves as an internal standard for normalizing 
MoMLV particle numbers. To compare the ratio of gRNA/7SL for the Gag and 
Gag-Pol complementation system to WT MoMLV, a plasmid containing a WT 
proviral MoMLV clone (pNCA) was transfected into ET cells, then virion RNA was 
harvested from the media and gRNA packaging was examined by RNAse 
protection assay (RPA) using a chimeric riboprobe containing sequences 
complementary to gRNA and 7SL (Fig III-5A). The results established a baseline 
for packaging that was consistent with values previously reported for MLV (99). 
 Next, the impact of altered MoMLV Gag:Gag-Pol polyprotein ratios on 
gRNA packaging was determined. As above, pΨ-MLV-Gagonly and pΨ-MLV-Gag- 
Polonly(PRD32S) were transfected into ET cells either alone or in combination with 
each other at various molar ratios along with the MoMLV vector pMΨPuro. 
MoMLV particle RNA was then harvested and gRNA packaging was examined by 




Figure III-5: Impact of MoMLV Gag:Gag-Pol ratio on gRNA 
packaging. (A) RPA of particle RNA harvested from ET cells 
transfected with WT MoMLV (pNCA). (B) Quantification of gRNA 
packaging is presented as a ratio of gRNA/7SL (with WT set to 100%) 
and represents a single experiment. (C) RPA of particle RNA harvested 
from ET cells transfected with the indicated Gagonly, and Gag-Polonly 
helpers (lanes 1 and 2) or co-transfected with the indicated ratio of 
Gagonly/Gag-Polonly helpers (lanes 3 through 9). The plasmid pMΨPuro 
was included in each transfection to serve as gRNA. (D) Quantification 
of gRNA packaging in (C) is presented as ratios of gRNA/7SL 
(normalized to 100% WT in (A) and (B)) and represents the results of 
two experiments. Error bars indicate the standard error of the means. 
Lane markers for RPAs include: undigested probe [P] (pEG467-10), 
RNA size markers [M], and digested probe-alone control [C]. gRNA and 




 Consistent with the results described above, co-expression of excess Gag 
and lower levels of Gag-Pol across a wide range of ratios resulted in efficient 
particle production (Fig III-5C, lanes 3 through 7), and particle production  
was attenuated (reflected by decreases in 7SL signal) when Gag-Pol represented 
50% or greater of the total protein (Fig III-5C, lanes 8 and 9). Packaged gRNA 
(Fig III-5B) had a ratio of gRNA/7SL for WT MoMLV similar to the gRNA/7SL ratio 
when pΨ-MLV-Gagonly and pΨ-MLV-Gag-Polonly(PRD32S) were transfected into ET 
cells at a 95%:5% ratio (Fig III-4D, lane 5). This result is consistent with the 
presumed 95%:5% Gag:Gag-Pol expression ratio in cells for WT MoMLV.  
 Additional quantification of gRNA/7SL revealed increasing amounts of 
gRNA packaged as the amount of Gag-Pol in particles increased from 1% to 10% 
of total viral polyproteins (Fig III-5D, lanes 3 through 7). Specifically, gRNA/7SL 
increased approximately 5 fold for particles containing 10% Gag-Pol compared to 
virions containing 100% Gag only (Fig III-5D). These results suggest that the 
Gag-Pol polyprotein may play a role in regulating the amount of gRNA packaged 
in virions. 
gRNA packaging function of the Gag-Pol polyprotein 
 My previous work showed that packaging of a full complement of gRNA 
requires that only a small fraction of the total MoMLV Gag molecules provide 
packaging competent NC (59). The experimental system used here allowed the 
question of whether either Gag or Gag-Pol could serve as this source of 
packaging-competent NC. To this end, a single mutation of Trp 35 within the 
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zinc-knuckle of NC was introduced into the Gagonly and Gag-Polonly expression 
constructs to produce pΨ-MLV-Gagonly(NCW35G) and pΨ-MLV-Gag-Polonly(NCW35G) 
respectively (Fig III-1). The Trp 35 mutation was selected based on previous 
studies showing that mutations of this residue lead to significant reductions in 
MoMLV gRNA packaging, but only nominally affected other assembly functions 
of NC (46, 59, 83) when virus was produced by transient transfection in human 
cells.  
 To determine if NCʼs packaging function could be provided in the context 
of the Gag-Pol polyprotein, combinations of Gag and Gag-Pol expression 
constructs containing WT or Trp 35 mutant NCs (NCW35G) were co-transfected 
into ET cells at 20:1 “WT-like” Gag:Gag-Pol ratios along with the MoMLV vector 
pMΨPuro. Under these conditions, particle production was low and background 
levels were too high to permit accurate gRNA quantification by RPA. Therefore a 
single-cycle infectivity assay was utilized to examine gRNA packaging indirectly. 
  For this assay, MoMLV particles were used to infect fresh target cells and 
provirus titer was determined (Fig III-6). Titer of virus containing NCWT Gag and 
NCWT Gag-Pol (Fig III-6, lane 5) was infectious whereas titer of virus containing 
W35G mutant NC in Gag and Gag-Pol was reduced to background levels (Fig III-
6, lane 8). The titer of virus containing NCWT Gag and NCW35G Gag-Pol was 
similar to that containing NCWT Gag and NCWT Gag-Pol (Fig III-6, lanes 5 and 6), 
suggesting that this NC mutation does not impact the function of Gag-Pol in this 
assay and confirming that the W35G NC mutation may be utilized to compare 
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Figure III-6: gRNA packaging function of the MoMLV Gag-Pol 
polyprotein. Titer of virus produced from ET cells transfected with the 
indicated Gagonly or Gag-Polonly helpers (lanes 1 thru 4) or co-
transfected with a 95%/5% ratio of the indicated WT or NCW35G 
Gagonly/Gag-Polonly helpers (lanes 5 through 9). Titer is presented as 
CFU/mL and represents the mean of at least three independent 





packaging functions of Gag and Gag-Pol despite previously shown defects in 
reverse transcription (59). 
 For virus containing NCW35G Gag and NCWT Gag-Pol, where the packaging 
competent NC was present only within the Gag-Pol polyprotein, the titer was ~2.5 
log units lower than thiters for NCWT Gag and NCWT Gag-Pol virus (Fig III-6, lanes 
7 and 5). However, when compared to virus where the packaging competent NC 
was present only within the Gag polyprotein, and represented 5% of the total 
protein, the titer was only approximately two-fold lower than that of NCW35G Gag/ 
NCWT Gag-Pol virus (Fig III-6, compare lanes 7 and 9). These results 
demonstrate that a packaging-competent NC can support virus replication when 
provided in the context of either the Gag or Gag-Pol polyprotein and suggest that 
NC in the context of either Gag or Gag-Pol may provide the gRNA packaging 
function for MoMLV. 
Limits of MoMLV gRNA packaging 
 The experiments described above demonstrated that alterations in the 
conserved Gag:Gag-Pol ratios and overexpression of Gag-Pol resulted in defects 
in MoMLV particle production. In order to test if alterations in Gag:gRNA ratios 
also resulted in defects in particle production, MoMLV particles were produced by 





Figure III-7: Limits of MoMLV gRNA packaging. (A) MoMLV particle 
release from cells co-transfected with the MoMLV helper pMΨ-MLV and 
increasing concentrations of the MoMLV vector pMΨPuro was 
determined by RT activity of media harvested from cells and normalized 
to helper RNA amounts in cells as determined by RPA. Quantification 
by phosphoimager analysis is shown relative to the helper alone control 
(lane 1) which is set to 100%. (B) RPA of RNA harvested from media, 
from cells transfected as above probed with the riboprobe pD1040-2. 
(C) Quantification MoMLV vector RNA packaging shown in (B) 
normalized to particle release shown in (A). The input molar ratio of 
helper and vector are indicated above each panel, with the amount of 
helper set to 1. The following concentrations of pMΨPuro were used in 
the experiments here: 0.02, 0.06, 0.18, 0.56, 1.67, and 5 µg. The total 
amount of input DNA in each transfection was kept constant by the 




Figure III-8: gRNA packaging in Ψ - MoMLV particles. RPA of 
RNA harvested from media from cells co-transfected with the 
MoMLV helper pMΨ-MLV and the MoMLV vector pMΨPuro (lane 1) 
or WT MoMLV (pNCA, lane 2). The RPA was co-probed with the 






MoMLV vector pMΨPuro. Particle production was then quantified by a reverse 
transcriptase (RT) assay (Fig III-7A). Minor reductions in particle production 
relative to the Ψ- helper alone (approximately two-fold or less) were observed 
across all concentrations of co-expressed input MoMLV vector plasmid (Fig III-
7A, lanes 1 through 7).  
 Next, gRNA packaging in MoMLV particles, produced as described above, 
was examined by RPA (Fig III-7B). Consistent with previous studies that 
demonstrated that the Ψ/DLS deletion (residues 215 to 368) in pMΨ-MLV results 
in gRNA packaging at ~1% of WT (86), MoMLV helper RNA derived from pMΨ-
MLV was efficiently packaged in the absence of the MoMLV vector pMΨPuro (Fig 
III-7B, lane 1). As the amount of Ψ+ gRNA (derived from the MoMLV vector 
pMΨPuro) co-expression increased, the amount of pMΨ-MLV helper RNA in 
particles correspondingly decreased (Fig III-7B and C, lanes 2 through 7).  
 Quantification of gRNA packaging (Fig III-7C), when normalized for 
particle production (Fig III-7A), showed that as the amount of co-transfected 
vector plasmid increased approximately 80-fold, the amount of gRNA packaged 
per particle increased approximately 25-fold (Fig III-7C, compare lanes 2 and 5).  
Increasing the amount of vector included in the transfection 250-fold did not 
further increase the amount of gRNA packaged per particle, suggesting the 
amount of gRNA packaged in this case represents the upper limit of gRNA 
packaging by MoMLV under these conditions (Fig III-7C, compare lanes 5 and 7), 
and that gRNA packaging is saturable. 
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 To compare the upper limit of gRNA packaging observed here to 
packaging by WT MoMLV, MoMLV particles were produced by co-transfecting 
ET cells with the helper pMΨ-MLV and 5 µg pMΨPuro (same condition as Fig III-
7B, lane 7) or with pNCA alone (WT MoMLV). Next, gRNA packaging was 
determined by RPA utilizing two riboprobes, one complementary to MoMLV 
gRNA and one to 7SL (Fig III-8). The observation that similar amounts (less than 
2-fold difference) of gRNA are packaged for WT MoMLV, compared to when a 
MoMLV vector is overexpressed (Fig III-8, lanes 1 and 2), suggests that the 
upper limit of gRNA packaging obverved in Fig III-7 is the amount of gRNA 
packaged by WT MoMLV. 
Impact of Ψ /DLS multiplication on MoMLV particle production and gRNA 
packaging 
 The above experiments demonstrated that alterations in Gag:gRNA 
expression ratios did not impact particle production, but the plateau in packaging 
levels suggested a maximal RNA packaging capacity. To address if the 
maximum was reached by RNA mass or by Ψ recognition, I tested if alterations in 
the Gag:Ψ/DLS ratio affected RNA packaging saturation levels. To this end, 
several MoMLV vectors containing additional copies of the native Ψ/DLS were 
constructed (Fig III-9). These vectors contained one, two, three, or four additional 





Figure III-9: Structure of MoMLV vectors containing multiple 
Ψ /DLSʼs. Diagram of MoMLV vectors used in the experiments 
described here. pMΨPuro is the parental MoMLV vector clone from 
which all other vectors were derived. pMΨPuro contains an SV40 driven 
puroR cassette in place of the viral genes. The vectors pM2xΨPuro, 
pM3xΨPuro, pM4xΨPuro, pM5xΨPuro contain two, three, four, and five 







MoMLV particles were produced by co-transfecting ET cells with the MoMLV 
helper pMΨ-MLV and each of the MoMLV vectors. Particle production from these 
cells was then examined by both RT assay (Fig III-10A) and western blot 
analysis (Fig III-10B). Only modest differences (approximately two-fold or less) in 
particle production were observed, as measured by both RT and western  
blot, for co-expression with all multiple Ψ/DLS containing MoMLV vectors (Fig III-
10A and B). 
 Next, the impact to MoMLV Ψ/DLS multiplication on gRNA packaging was 
examined. RNA for analysis by RPA was isolated from MoMLV particles that 
were produced as described above (Fig III-10C). gRNA packaging observed for 
the MoMLV vectors containing two, three, and four Ψ/DLSʼs was 
indistinguishable (Fig III-10C). In contrast, approximately five-fold reductions in 
gRNA packaging were observed for the vector pM5xΨPuro (Fig III-10C, lane 5). 
Figure III-10: Impact of Ψ /DLS multiplication on MoMLV particle 
production and gRNA packaging. (A) RT activities of media and (B) 
western blot of virus lysates produced from from cells co-transfected 
with the indicated MoMLV vector and the MoMLV helper pMΨ-MLV. (C) 
RPA of RNA harvested from pelleted virions harvested from cells co-
transfected with the indicated MoMLV vector and the MoMLV helper 
pMΨ-MLV. (D) RPA of RNA harvested from from cells co-transfected 
with the indicated MoMLV vector and the MoMLV helper pMΨ-MLV. (E) 
gRNA packaging data normalized to virion production by either RT 
activity or p30 CA. Quantification by phosphorimager analysis of RT 
activity, densitometry of WB band intensities, and phosphorimager 
analysis of gRNA packaging by RPA are all shown relative to the 
pMΨPuro vector which is set to 100%. Where present, error bars 
indicate that quantification represents the mean of at least two 
experiments and represent the standard error of the means. 
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Normalized for particle production relative to the WT vector pMΨPuro, 50-80% 
reductions were observed (Fig III-10E). Taken together, these results suggest 
that the multiplications of MoMLV Ψ/DLSʼs on the gRNAs tested here did not 
significantly alter particle production or gRNA packaging until there were five 
Ψ/DLSʼs on a single gRNA. 
Discussion 
 The MoMLV RNP is composed of roughly 2,500 Gag molecules, 125 Gag-
Pol molecules, and one gRNA dimer (16). The counting mechanism that 
accounts for the asymmetry between the Gag-Pol molecules and Gag as well as 
the gRNA dimer and Gag is unknown. The goal of the present study was to test 
the hypothesis that the copy number of Gag-Pol and the gRNA in the MoMLV 
were determined by dissimilar mechanisms. Specifically, I predicted that Gag-Pol 
is incorporated randomly and the ratio of Gag:Gag-Pol in MoMLV is due to 
intracellular expression ratios. However, gRNA incorporation is highly specific, 
and thus I predicted that RNA packaging is not strictly dependent on intracellular 
Gag:gRNA expression ratios. 
 The Gag:Gag-Pol co-expression system described here allowed an 
examination of the stoichiometry and incorporation of Gag-Pol in MoMLV virions. 
Using the pΨ-MLV(PRD32S) helper revealed that Gag-Pol was present in virions at 
~6% the total Gag under native Gag:Gag-Pol expression conditions. This 
matches the reported readthrough rate of the MoMLV gag stop-codon that is 
required to produce Gag-Pol (54, 58). When the Gag:Gag-Pol ratios were 
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manipulated, the numerical proportion of Gag-Pol in virions relative to Gag 
matched the input, thereby suggesting that the incorporation of Gag-Pol into 
virions is principally a stochastic process. This result supports the hypothesis that 
the conserved copy number of Gag-Pol in MoMLV particles is due to random 
incorporation of the polyproteins. 
 In contrast to the results observed for Gag-Pol, when MoMLV gRNAs were 
overexpressed relative to Gag, gRNA incorporation was not recruited in 
proportion to expression levels, since saturable limits of gRNA packaging were 
observed. These results support the hypothesis that the conserved copy number 
of gRNAs within MoMLV particles is due to specific incorporation of the gRNA 
dimer that results from specific Gag:Ψ/DLS interactions. As gRNA expression in 
cells increased, the amount of gRNA per particle increased to a saturable upper 
limit. Although the results did not resolve the question of whether or not more 
empty particles were produced when gRNAs are expressed at low levels, the 
finding that RNA packaging plateaued at a level similar to that observed for WT 
MLV suggests that packaging is limited to a single RNA dimer for MLV. 
 The gRNA overexpression experiments described here also provide a 
numerical prediction of the ratio of MoMLV gRNA and mRNA within the host cell. 
Previous studies have suggested that MLV gRNAs and mRNAs exist in two 
distinct non-equilibrating pools (84). However, the molar proportion of these two 
pools is unknown. The experiments here suggest that saturable packaging levels 
are achieved when the gRNA (vector) pool represents 10-15% of the mRNA 
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(helper) pool (Fig III-7). If MoMLV replication has evolved to ensure replication 
occurs naturally under conditions of optimal gRNA/mRNA ratios, these findings 
suggest that ~15% of the total unspliced MoMLV RNA resides in the gRNA pool. 
 The precise molecular mechanism that regulates the single gRNA dimer 
packaging specificity is unknown. An additional novel gRNA packaging 
phenotype observed here may shed light on this mechanism. As the amount of 
MoMLV Gag-Pol present in virions increased, the amount of gRNA per virion 
correspondingly increased. These results suggest that maintenance of the 
conserved 20:1 Gag:Gag-Pol ratio may be critical to regulate the amount of 
gRNA packaged into virions. The results suggest that the Gag-Pol polyprotein 
and the ratio of Gag to Gag-Pol may be involved in regulating this packaging 
specificity. 
 If the single dimer packaging specificity is dependent on specific 
interactions between Gag and the Ψ/DLS of the gRNA dimer, then duplication of 
the Ψ/DLS may negatively impact MoMLV production or gRNA packaging. My 
results showed that multiplication of the MoMLV Ψ/DLS did not impact either 
MoMLV particle production or gRNA packaging, except in a single case: when 
five Ψ/DLS sites were present on a single MoMLV gRNA. This suggests that 
even in the presence of additional Ψ/DLS sites, MoMLV Gag was able to 
maintain gRNA packaging specificity. One caveat of these experiments is that it 
is unknown whether or not the non-native Ψ/DLS sites on the multiple Ψ/DLS 
vectors form additional intra- or inter-molecular dimer linkages.   
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 When MoMLV Gag and Gag-Pol were produced from two distinct 
expression constructs, marked defects in virus particle production and infectivity 
were observed at equimolar ratios of the two polyproteins and when Gag-Pol 
represented the majority polyprotein. These results are consistent with previous 
studies with HIV-1 (49, 121). When Gag-Pol is overrepresented in cells, newly 
assembling virions may be disrupted due to improper membrane curvature at 
sites of assembly or to the inability of assembled virions to accommodate the 
larger (relative to Gag) Gag-Pol molecule. The aberrant virion morphology 
observed for HIV-1 when Gag-Pol is overrepresented in cells is consistent with 
this notion (49).  
 Two interesting phenotypes were observed here when MoMLV Gag was 
expressed from the pΨ-MLV-Gagonly helper construct. First, an approximately 
five-fold decrease in cell associated Gag was observed in cells for pΨ-MLV-
Gagonly relative to pΨ-MLV. The decrease in cell associated Gag could potentially 
result from differences in nuclear export of the MoMLV RNAs produced from pΨ-
MLV-Gagonly and pΨ-MLV. Previous studies have suggested that sequences 
within the 5ʼ-UTR may function in nuclear export (4), however, other sequences 
within the MoMLV RNA (that have been removed in the pΨ-MLV-Gagonly helper) 
may also be important for efficient nuclear export. 
 Second, MoMLV particles produced from pΨ-MLV-Gagonly yielded low but 
reproducible proviral titers that were abolished in the presense of AZT. These 
results suggest that reverse transcription products were actively produced after 
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infection with MoMLV particles presumably lacking Pol. One explanation for this 
phenotype is that MoMLV particles produced by pΨ-MLV-Gagonly contained 
functional Pol derived from an endogenous retrovirus (ERV) source. The human 
genome contains substantial ERV sequences (estimated to represent ~8% of the 
total genome), many of which retain protein coding capacity (reviewed in (137)). 
Moreover, retroviral infection has been shown to upregulate ERV RNA and 
protein expression (136) thereby suggesting that the conditions described here 
may be condusive for the incorporation of ERV derived Pol into MoMLV particles. 
 Additional experiments here revealed that the Gag-Pol polyprotein may 
interact directly with the gRNA, since viral titers were indistinguishable when a 
packaging competent NC was provided either in the context of Gag or Gag-Pol 
polyproteins. Previous studies with HIV-1 have suggested that HIV-1 Gag-Pol 
may not interact directly with RNA (66) and that Gag-Pol is recruited into 
assembling virions via CA:CA interactions (reviewed in (53)). However, work with 
the yeast retrotransposon Ty3 showed that the “zinc-knuckle” motif of NC could 
support retrotransposition when provided either in the context of Gag or Gag-Pol 
(102). My work here provides evidence that at least for MoMLV, Gag-Pol may 
interact with gRNA, since a functional NC could support single-cycle infectivity in 
the context of either Gag or Gag-Pol. 
 In summary, my experiments showed that the stoichiometry of Gag-Pol in 
MoMLV virions matches the conserved readthrough rate in cells and that the 
incorporation of Gag-Pol into virions is principally stochastic. Furthermore, my 
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studies confirmed the importance to virion production of maintaining the 
conserved 20:1 Gag:Gag-Pol ratio and suggest that Gag-Pol plays a direct role in 
regulating the amount of gRNA packaged, possibly through a direct interaction 
with gRNA itself. These findings underscore the importance of Gag-Pol in 
MoMLV assembly and suggest that pharmacologic skewing of protein ratios 
could inhibit virus replication. Furthermore, I contrasted the mechanism of 
incorporation of MoMLV Gag-Pol with that of gRNAs, since gRNA incorporation 
was specific as opposed to stochastic. Finally, my findings showed that MoMLV 
particle production was not significantly altered when the proportion of Gag to 
gRNA or Ψ/DLSs was changed. 
Materials and Methods 
Cells and Transfectons.  
ET cells are 293T cells that constitutively express murine ecotropic 
envelope (106). D17/pJET cells are canine osteosarcoma cells that constitutively 
express murine ecotropic receptor. Cells were maintained in Dulbeccoʼs modified 
Eagleʼs medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum 
(Gemini) (for ETs) or 10% bovine serum (Invitrogen) (for D17/pJETs), 100U/mL 
penicillin, and 100 µg/mL streptomycin (Invitrogen). Cells were grown at 37°C 
with 5% CO2 in a humidified incubator. Transfections were carried out using 






The MoMLV helper pΨ-MLV (aka pAM37-9) was derived from pNCA 
(Colicelli and Goff 1988) and contains a deletion in the packaging signal region 
from nucleotides 215-368 (106). All other MoMLV helpers described here were 
derived from pΨ-MLV. pΨ-MLV-Gagonly (aka pSD50-1) contains a deletion that 
removes the pol and all but the last 100 nucleotides of the env reading frames. In 
addition, it contains a four-nucleotide substitution (GGAG to ACGC) immediately 
downstream of the Gag stop-codon to prevent read-through via termination 
suppression. pΨ-MLV-Gag-Polonly (aka pSD45-1) contains a deletion that 
removes all but the last 100 nucleotides of the env reading frame and a mutation 
that eliminates the Gag stop-codon. 
A restriction fragment encompassing the W35G NC mutation of 
pGPP(W35G) (aka pEG479-1) (59) was used to introduce the W35G mutation 
into the following MoMLV helpers: pΨ-MLV(NCW35G) (aka pSFJ346-1), pΨ-MLV-
Gagonly(NCW35G) (aka pSFJ22-1), and  pΨ-MLV-Gag-Polonly(NCW35G) (aka 
pSFJ23-1). A similar strategy was employed to introduce the W35G NC mutation 
into pΨ-MLV(NCW35G,PRD32S) (aka  pSFJ370-1) and pΨ-MLV-Gag-
Polonly(NCW35G,PRD32S) (aka pSFJ230-7). This was followed QuickChange II 
(Stratagene) site-directed mutagenesis to introduce the D32S mutation into PR. 
The PR mutations in pΨ-MLV(PRD32S) (aka pSFJ369-1) and pΨ-MLV-Gag-
Polonly(PRD32S) (aka pSFJ229-7) were also introduced by site-directed 
mutagenesis. Sequencing confirmed the products of site-directed mutagenesis. 
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The MoMLV vector pMΨPuro (aka pAM86-5) contains an SV40 driven puromycin 
resistance cassette in the place of the viral genes and has been described 
previously (68). 
The MoMLV vectors pM2xΨPuro (aka pSFJ98-3), pM3xΨPuro (aka 
pSFJ295-1), pM4xΨPuro (aka pSFJ298-3), and pM5xΨPuro (aka pSFJ299-5) 
contain one, two, three, and four Ψ/DLS regions (in addition to the native Ψ/DLS) 
respectively. To produce these vectors, a PCR fragment encompassing the 
Ψ/DLS region of pNCA (from nucleotides 199-621) was generated that contained 
built-on BglII and BamHI ends. The PCR fragment was subcloned into pUC19 
and verified by sequencing. The Ψ/DLS region was then removed by BglII/BamHI 
digestion and concatamerized. Ψ/DLS concatamers containing two, three, and 
four Ψ/DLS regions in the same orientation were then selected and inserted into 
the BamHI site of pMΨPuro. 
The riboprobes pEG467-10 and pD1040-2 are derivatives of pBSII SK(+) 
(Stratagene) and contain PCR or restriction fragments inserts respectively (38, 
123). The PCR fragment insert in pEG467-10 includes complementarity to 
portions of both MoMLV 5ʼ-UTR (nt 55-214) and 100nt of 7SL RNA (38). The 
restriction fragment insert in pD1040-2 is complementary to 330bp (MscI to 
BsrBI) of MoMLV Gag MA (123).  
Virus and Cell Isolation.  
Tissue culture supernatents were harvested at 48 h post transfection for 
isolation of virus by sucrose-cushion centrifugation (64). Viral pellets were either 
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resuspended in TRIzol reagent (Invitrogen) for RNA isolation and subsequent 
RNAse protection assays (RPA) or resuspended in RIPA lysis buffer (1% NP40, 
0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 150mM Nacl, 50mM 
Tris [pH7.5]) supplemented with 1X protease inhibitor cocktail tablet (Roche) and 
1 mM phenylmethylsulfonyl fluoride for western blotting. Cells were harvested 48 
h post transfection in either RIPA lysis buffer as described previously (59) to 
produce cell protein lysates for western blotting or in TRIzol reagent (Invitrogen) 
for RNA isolation and subsequent analysis by RPA. Where applicable, virus was 
quantified in tissue culture supernatents using an exogenous reverse 
transcriptase (RT) assay (38) based on a previously described protocol (134). 
Western Blotting.  
 Cell and virus lysates were resolved by SDS-PAGE, transferred to 
polyvinylidene fluoride (PVDF; Bio-Rad) membranes, blocked, blotted, and 
detected using the Licor Odyssey system (Li-Cor Biosciences), as previously 
described (59). The following primary antibodies were used: (1) rat mAb against 
MoMLV p30 CA, which was derived from hybridoma supernatants (from Bruce 
Chesebro: ATCC clone R187), and (2) mouse beta-actin mAb (Ambion: 
AM4302). Secondary antibodies included (1) goat anti-rat IRDye 800CW and 
(2) goat anti-mouse IRDye 680 (Li-Cor Biosciences). 
RNAse Protection Assay (RPA). 
 Riboprobes were produced by first linearizing the plasmid pEG467-10 (see 
above) with HindIII and then in vitro transcribing them using T3 RNA polymerase 
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(Promega) and [α-32P]-rCTP (Perkin-Elmer). The riboprobe pEG467-10 protects 
163 nt of MoMLV gRNA and 100 nt of 7SL RNA. Hybridization of riboprobes with 
sample RNA, RNAse digestion, and resolution was carried out as described 
previously (86).  
Infections.  
 For the single cycle infectivity assay, virus produced in ET cells was used 
to infect D17/pJET target cells. Infection and puromycin selection conditions have 
been described previously (59). Infectious units are represented as colony 
forming units per milliliter (CFU/mL). 
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Chapter IV  
Concusions and Future Directions 
Dissertation Overview 
 The Moloney murine leukemia virus RNP is composed of a 20:1 mixture of 
Gag and Gag-Pol polyproteins plus a dimeric RNA genome. The putative copy 
numbers of these RNP constituents are ~2,500 Gag molecules, ~125 Gag-Pol 
molecules (16, 132), and precisely one gRNA dimer (19). Presumably, each of 
the ~2,500 Gag molecules possesses intrinsic potential for high-affinity 
interactions required to package gRNA, due to the presence of an RNA binding 
motif within NC, as well as potential to recruit Gag-Pol into assembling virions, 
due the presence of Gag-Pol interacting motifs within CA. The mechanisms that 
account for the drastic asymmetry in the proportions of Gag, Gag-Pol and gRNA 
within the RNP are unknown. The overall goal of this dissertation was to define 
parameters that are responsible for these molecular proportions in MoMLV. 
  Studies with MoMLV and HIV-1 suggest that only a very small fraction of 
the ~2,500 Gag molecules in a virion engage the gRNA dimer with high affinity 
during virus assembly (61, 86). These studies support a model whereby the 
retroviral Gag molecules may be separated into two distinct pools: one that 
participates in high-affinity gRNA interactions and one that does not. The goal of 
the work described in Chapter II (59) was to manipulate the molecular 
proportions of Gag molecules, in the context of the two-pool model described 
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above, and examine the effects on gRNA packaging. Specifically, I tested the 
hypothesis that specific RNA binding capability is required in only a small fraction 
of the ~2,500 Gag molecules to package gRNA. 
 To that end, I developed an experimental system that allowed two pools of 
Gag molecules to be co-expressed in cells: one that was able to participate in 
high-affinity gRNA interactions and one that was not. By manipulating the 
molecular proportions of the two pools of Gag molecules experimentally, I 
showed that a full complement of packaging-competent Gag was not required to 
package gRNA, but the required size of the pool was greater than predicted by 
previous studies (61, 86). 
 I hypothesized that regulation of the copy number of MoMLV Gag-Pol 
molecules and of the gRNA dimer in the RNP occur via two different 
mechanisms. First, the ratio of Gag and Gag-Pol in newly forming RNPs is 
dependent on the conserved expression ratios of Gag and Gag-Pol in cells. 
Second, the highly specific selection of a single gRNA dimer into the MoMLV 
RNP is not strictly dependent of the expression ratios of Gag and gRNA in cells, 
and instead relies on the specific high-affinity interactions between a small pool 
of Gag molecules (Chapter II) and the Ψ/DLS of the gRNA dimer. 
 The goal of the work described in Chapter III was to manipulate the 
molecular proportions of (1) Gag and Gag-Pol, (2) Gag and gRNA, and (3) Gag 
and Ψ/DLS, examine the incorporation of each of these molecules into the 
MoMLV RNP, and determine the impact of alterations of these ratios on MoMLV 
particle production, gRNA packaging, and infectivity. Specifically, experiments 
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were designed to test the hypothesis that Gag-Pol and gRNA are incorporated by 
two disparate mechanisms.  
 To that end, I developed an experimental system to allow manipulation of 
the molecular proportions of Gag, Gag-Pol, gRNA, and the Ψ/DLS in MoMLV 
RNPs. My results showed that the incorporation of Gag-Pol into the MoMLV RNP 
did indeed represent a stochastic sampling from the cell, since the ratio of Gag 
and Gag-Pol in RNPs matched the intracellular expression ratios. Additionally, I 
showed that when Gag-Pol was overrepresented relative to Gag in the MoMLV 
RNP, particle production was impaired. This observation was in contrast to when 
the ratio of Gag to gRNA or Gag to Ψ/DLS was altered in the RNP. In these 
cases, upper limits of gRNA packaging were observed and no defects in particle 
production were observed. 
 
The major findings highlighted in this dissertation, including and in 
addition to those described above, are presented as follows: 
 
Chapter II 
•  MoMLV gRNA packaging-competent Gag and mutant gRNA packaging-
incompetent Gag co-assemble to form particles. 
•  Mutations that render MoMLV Gag packaging-incompetent do not affect gRNA 
dimer formation or gRNA stability. 




•  MoMLV gRNA packaging requires 5-10 fold more packaging-competent Gag in 
cultured cells than predicted by in vitro binding studies. 
 
Chapter III 
•  Separate expression of MoMLV Gag and Gag-Pol supports particle production, 
gRNA packaging, and virus infectivity. 
•  Incorporation of Gag-Pol into MoMLV virions is stochastic over a broad range 
of Gag and Gag-Pol coexpression ratios. 
•  Inversion of the conserved molecular proportions of MoMLV Gag and Gag-Pol 
results in reductions in particle production and infectivity. 
•  Alterations in the molecular proportion of MoMLV Gag-Pol relative to Gag 
results in molar alterations in gRNA packaging. 
•  The RNA binding motif of NC supports MoMLV replication in the context of 
either Gag or Gag-Pol, suggesting that the NC of Gag-Pol may serve to package 
gRNA. 
•  Incorporation of gRNAs into MoMLV particles is not stochastic, since packaging 
plateaued at an upper limit similar to that observed for WT MLV. 
•  Overexpression of MoMLV gRNAs or multiple copies of the Ψ/DLS on the 






 As described above, the goal of the work presented in Chapter II was to 
test the hypothesis that only a small fraction of the ~2,500 Gag molecules in an 
MoMLV RNP are required to package gRNA. In order to test this hypothesis, I 
developed an experimental system whereby MoMLV virions could be produced 
that contained phenotypic mixtures of two types of Gags: packaging-competent 
and packaging-incompetent. By manipulating the ratios of the two types of Gags 
in MoMLV virions, the threshold limit of packaging-competent Gag required for 
gRNA packaging could be determined. My results support the hypothesis; 
MoMLV gRNA is packaged even when most of the Gag is not packaging-
competent. 
 I first generated a packaging-incompetent Gag molecule by introducing a 
single amino-acid mutation (W35G) within the zinc-knuckle of NC (Fig II-1). 
Introducing this mutation into Gag resulted in virus that was defective in gRNA 
packaging (Fig II-3A). However, this mutation did not significantly alter virus 
production (FigII-2B,C, and D) or gRNA dimerization and stability (Fig II-3B) 
when expressed by transient transfection in human cells. Next, packaging-
competent WT NC Gag and packaging-incompetent W35G NC Gag were co-
expressed to produce virions that contained phenotypic mixtures of WT and 
W35G NC Gag (Fig II-5B) and that were infectious (Fig II-4A and B and Fig II-7A 
and B). Finally, utilizing phenotypically mixed MoMLV, I determined that a full 
complement of WT NC was not required to package gRNA, however, the amount 
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of WT NC required to package gRNA was greater than predicted (Fig II-6A and 
B). 
Future Directions 
 In vitro binding studies suggested that ≤1% of Gag molecules may be 
required to bind the gRNA dimer with high-affinity for gRNA packaging during 
MoMLV assembly (86). My virus results suggested that the minimum Gag 
required was ≥5-10%. There are two potential explanations for this discrepancy. 
First, more high-affinity Gag-gRNA interactions may be required to package 
gRNA during virus replication. Second, the presence of mutant Gag may result in 
a defect whereby the number of functional Gag molecules required for gRNA 
packaging is increased. 
   In order to differentiate between these two possibilities, additional 
experiments could be performed to estimate the number of Gag molecules 
required to package gRNA in cultured cells. Using methods similar to those 
employed for HIV-1 by Jouvenet et al. (61), MoMLV gRNAs could be constructed 
that contain stem loops that bind the bacteriophage MS2 protein. These RNAs 
could then be visualized by fluorescence microscopy in cells that express MS2-
GFP and their localization relative to Gag molecules in cells could be determined. 
The sensitivity of this assay allowed for estimation of the amounts of HIV-1 Gag 
(one dozen Gag molecules or fewer) required to recruit gRNA for packaging 




 My results are consistent with a model where two pools of Gag are 
present within cells: one that participates in high-affinity gRNA interactions and 
one that does not. However, the mechanism that causes the separation of a 
single population of Gag into these pools is unknown. It is possible that the pool 
of Gag that participates in high-affinity gRNA interactions is not different from the 
pool of Gag that does not, and is defined simply upon binding to the gRNA high-
affinity binding sites. An alternate explanation is that the pool of Gag that 
participates in high-affinity gRNA interactions is preexisting and requires an 
active mechanistic separation. Evidence and future experiments to explore the 
latter explanation is provided in the Future Directions section of Chapter III 
below.  
 Although not directly related to the specific goals of this dissertation, two 
additional phenotypes were observed in the work described in Chapter II. First, 
the W35G NC mutation resulted in defects in reverse transcription (Fig II-8). My 
hypothesis is that the W35G NC mutation impairs the chaperone function of NC 
during reverse transcription. Investigating this error in reverse transcription could 
reveal novel information about NC’s chaperone function. 
 Second, a major difference in virus production for the W35G NC Gag was 
observed in human cells versus murine cells (Fig II-2). Many cellular factors 
regulate the trafficking of Gag to sites of retrovirus assembly and support 
retrovirus budding (reviewed in (30, 101)). The phenotype observed for W35G 
NC Gag in murine cells may result from the improper recruitment of specific 
cellular factors required for viral protein trafficking or budding due to the mutation 
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in NC. Further flouresence microscopy studies examining WT and W35G NC 
Gag trafficking in human and murine cell types could reveal differences in protein 
trafficking to sites of assembly. Furthermore, electron microscopy could be used 
to examine budding defects of WT and W35G Gag MoMLV in human and murine 
cells. 
Chapter III 
 The goal of the work presented in Chapter III was to test the hypothesis 
that Gag-Pol and gRNA are incorporated by two disparate mechanisms. I tested 
this hypothesis by developing an experimental system to manipulate the 
molecular proportions of (1) Gag and Gag-Pol, (2) Gag and gRNA, and (3) Gag 
and Ψ/DLS in MoMLV. By manipulating the proportions of these molecules in 
MoMLV particles, the mechanism of incorporation was examined and the 
resulting affects of altering these ratios on MoMLV production, gRNA packaging, 
and infectivity were determined. The results supported the hypothesis that 
MoMLV Gag-Pol and gRNA are incorporated by disparate mechanisms. 
 I first developed an experimental system whereby the Gag and Gag-Pol 
polyproteins were coexpressed using two separate constructs (Fig III-1 and Fig 
III-2). This allowed me to manipulate the molecular proportions of the two 
molecules and examine the impacts on gRNA packaging. I showed that co-
expression of Gag and Gag-Pol from two separate constructs could support virus 
production (Fig III-3) and that this virus was capable of supporting a single round 
of replication (Fig III-4). Furthermore, when the ratio of Gag and Gag-Pol was 
manipulated, the incorporation of Gag-Pol into virions was stochastic (Fig III-3). 
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Moreover, when the amount of Gag-Pol outnumbered Gag, virion production 
decreased (Fig III-3). 
  In addition, I provided indirect evidence that either Gag or Gag-Pol could 
serve to bind gRNA for packaging by showing that single cycle infectivity of 
MoMLV could be supported by a RNA binding competent NC provided on either 
Gag or Gag-Pol (Fig III-6). Finally, I showed that when the ratio of Gag and Gag-
Pol is altered, the amount of gRNA packaged in virions is changed (Fig III-5). 
Specifically when the amount of Gag-Pol in virions increased, gRNA amounts in 
virions also increased (Fig III-5). 
 Next, I developed an experimental system to manipulate the ratio of Gag 
to gRNA and Gag to Ψ/DLS. First, gRNAs were overexpressed in cells to alter 
their proportion in MoMLV particles (Fig III-7). When gRNAs were overexpressed, 
particle production was not affected (Fig III-7), however, gRNA packaging per 
particle increased to an upper threshold limit (Fig III-7). Second, MoMLV vectors 
were constructed to contain various multiples of the Ψ/DLS site (Fig III-9) in order 
to manipulate the ratio of Gag to Ψ/DLSʼs on gRNAs (Fig III-10). Multiple copies 
of the MoMLV Ψ/DLS on a single gRNA did not impact particle production or 
gRNA packaging (Fig III-10) except when five Ψ/DLSs were present on a single 
MoMLV gRNA. 
Future Directions 
 The Gagonly and Gag-Polonly expression system described above is an 
artificial system in the sense that Gag and Gag-Pol are normally expressed in cis 
from a single viral RNA. Studies where mutations were introduced in the RNA 
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pseudoknot regulating MoMLV gag stop codon readthrough resulted in altered 
Gag/Gag-Pol ratios (54). The gRNA packaging phenotype of MoMLV containing 
these mutations could be determined as described in Chapter III. If the 
readthrough mechanism that regulates the molecular proportions of Gag and 
Gag-Pol also lead to altered Gag/gRNA proportions, then the prediction is that 
pseudoknot mutations that alter Gag/Gag-Pol proportions would also alter 
Gag/gRNA proportions. 
 The results described in Chapter II are consistent with a model where two 
pools of Gag are present within cells: one that participates in high-affinity gRNA 
interactions and one that does not. Results in Chapter III provide a potential 
mechanistic explanation for the separation of the two pools of Gag. In Chapter III, 
I observed that when the amount of MoMLV Gag-Pol present in virions 
increased, the amount of gRNA per virion correspondingly increased. Itʼs 
possible that Gag:Gag-Pol interactions may drive Gag molecules towards a 
gRNA high-affinity binding fate and having the appropriate ratio of Gag:Gag-Pol 
results in an appropriate number of Gag molecules binding the MoMLV Ψ/DLS 
with high affinity. The flouescence microscopy experiments designed to examine 
Gag:gRNA interactions described above could be expanded to test whether or 
not Gag-Pol is present within these initial Gag:gRNA complexes.  
 Results described in Chapter III also showed that gRNA packaging in 
MoMLV reached a saturable upper limit (when gRNAs were expressed in trans) 
similar to that observed for WT MoMLV (when gRNAs were expressed in cis). 
Future experiments could be designed to determine whether the intracellular 
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ratios of Gag to gRNA are similar in each case. This would reveal whether the 
selectivity of gRNA incorporation is different for the co-expression system versus 
WT MoMLV.  
 Previous studies have shown that when a HIV-1 Ψ/DLS site was inserted 
into a gRNA in addition to the native Ψ/DLS gRNA, monomers appeared within 
newly formed virions as determined by non-denaturing northern blotting (117). In 
that case, ~30-40% of the gRNA within the virions was monomeric, while the 
remaining gRNA was dimeric (117). Furthermore, the total gRNA packaged 
(normalized to virion amounts) remained relatively unchanged relative to WT 
gRNA (117). Additional experiments showed that when two non-native HIV-1 
Ψ/DLS sites were inserted into a gRNA that had its native Ψ/DLS removed, 
gRNA monomers appeared exclusively in newly formed virions (116). Moreover, 
the amount of gRNA packaged (normalized to virion amounts) was cut roughly in 
half relative to WT gRNA in this case (116).  
 These results suggest that when a native HIV-1 Ψ/DLS is present on the 
gRNA in addition to a non-native Ψ/DLS, some intra-molecular Ψ/DLS 
interactions may occur in addition to inter-molecular Ψ/DLS interactions, resulting 
in the packaging of gRNA monomers. In addition, they suggest that when two 
non-native Ψ/DLSs are present on the gRNA in the absence of a native Ψ/DLS, 
only intra molecular Ψ/DLS interactions occur, resulting in the exclusive 
packaging of monomers (114). These presumably are present in each virion as a 
single gRNA species, since the quantity of gRNA in virions is cut roughly in half 
in this case (however the copy number of gRNAs was not specifically determined 
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in these studies) (116).Taken together, these studies point to a model whereby 
one dimer linkage consisting of two joined Ψ/DLS sites is necessary to specify 
single-dimer packaging specificity. This is in contrast to a model whereby 
recognition of two HIV-1 gRNAs is necessary to specify single-dimer packaging 
specificity. 
 Future experiments could be performed to determine if the MoMLV 
vectors containing multiple Ψ/DLS sites (Chapter III) are packaged as monomers, 
similar to HIV-1. MoMLV vectors could also be constructed to contain a deletion 
of the native Ψ/DLS site and the addition of two non-native Ψ/DLS sites. If 
MoMLV is similar to HIV-1, I would predict that MoMLV would package 
exclusively monomers in this case. These experiments would help to refine the 
model that describes the “counting” mechanism that regulates the single-dimer 
packaging specificity for retroviruses. 
Impact of Ψ /DLS duplication in the reverse orientation from the native 
Ψ /DLS on MoMLV particle production and gRNA packaging. 
 Work described in Chapter III examined the impact of MoMLV Ψ/DLS 
multiplication on particle production and gRNA packaging. The MoMLV vectors 
used in Chapter III contained additional Ψ/DLS sites in tandem, in the same 
orientation as the native Ψ/DLS site. I also tested whether the orientation of the 
non-native Ψ/DLS site in the vector containing two Ψ/DLS’s altered the 
phenotype observed in Chapter III. Preliminary experimental results reported in 





Figure IV-1: Impact of Ψ /DLS duplication in the reverse orientation 
from the native Ψ /DLS on MoMLV particle production and gRNA 
packaging. (A) Structure of MoMLV duplicate psi vector used here. (B) 
RT activities of media and (C) western blot of virus lysates produced from 
from cells co-transfected with the indicated MLV vector and the MLV 
helper pMΨ-MLV. (D) RPA of RNA harvested from pelleted virions 
harvested from cells co-transfected with the indicated MLV vector and the 
MLV helper pMΨ-MLV. (E) gRNA packaging data represented normalized 
to virion production by either RT activity or p30 CA. Quantification by 
phosphorimager analysis of RT activity, densitometry of WB band 
intensities, and phosphorimager analysis of gRNA packaging by RPA are 
all shown relative to the pMΨPuro vector, which is set to 100%. Where 
present, error bars indicate that quantification represents the mean of at 




orientation from the native Ψ/DLS resulted in defects in particle production and 
gRNA packaging.    
 First, I constructed a MoMLV vector called pM2xΨrevPuro (derived from 
pMΨPuro) that contains one additional non-native Ψ/DLS site in the opposite 
orientation as the native Ψ/DLS site (Fig IV-1A). MoMLV particles were produced 
by co-transfecting ET cells with the MoMLV helper pΨ-MLV and the MoMLV 
vector pMΨPuro or pM2xΨrevPuro. Virion production from these cells was 
examined by both RT assay (Fig IV-1B) and western blot analysis (Fig IV-1C). 
The MoMLV vector pM2xΨrevPuro yielded an ~4-5 fold defect in virion 
production relative to the WT MoMLV vector (Fig IV-1A and B, lane 3).  
  Next, the impact of MoMLV Ψ/DLS duplication (for pM2xΨrevPuro) on 
gRNA packaging was examined. RNA was isolated from virions that were 
produced as described above for analysis by RPA (Fig IV-1D). An approximately 
5-10 fold reduction in gRNA packaging was observed for pM2xΨrevPuro relative 
to pMΨPuro (Fig IV-1D). gRNA packaging decreased approximately three fold 
when normalized for particle production by RT activity or western blot (Fig IV-1E). 
 To determine whether the defect in particle production for pM2xΨrevPuro 
virus was due to decreased expression of the vector in cells, an RPA was 
performed on RNA harvested from cells transfected as described above. Only 
modest differences (approximately two-fold or less) in vector RNA expression 
levels were observed in cells by RPA for all MoMLV helpers (data not shown), 
suggesting that differences in particle production were not due to defects in 





Figure IV-2: Impact of Ψ /DLS duplication in the reverse orientation from the 
native Ψ /DLS on MoMLV Gag localization. HeLa cells expressing MoMLV 
Gag-YFP, the MoMLV helper pΨ-MLV, and the following MoMLV vectors: (A) 
pMΨPuro, (B) pM2xΨPuro, or (C) pM2xrevΨPuro. 
 
 101 
pM2xΨrevPuro was due to mis-localization of Gag during particle assembly, we 
used fluorescence microscopy and determined Gag localization in HeLa cells 
transfected with the MoMLV helper pΨ- MLV, a yellow fluorescent protein-tagged 
MoMLV Gag construct (Gag-YFP), and either of the following three MoMLV 
vectors: pMΨPuro, pM2xΨPuro, and pM2xΨrevPuro. We saw no differences in 
Gag-YFP localization in cells transfected with either of the three constructs (Fig 
IV-2), suggesting that Gag mis-localization was not the cause of the defect in 
particle production for pM2xΨrevPuro. 
 The defect in MoMLV particle production observed here may potentially be 
explained by innate immune sensing in cells transfected with pM2xΨrevPuro. 
The inclusion of two Ψ/DLS sites in opposite orientation may result in the 
formation of extensive double stranded RNA (dsRNA) secondary structures that 
may be recognized as pathogen-associated molecular patterns (PAMPs) 
(reviewed in (82)). In host cells, dsRNA PAMPs may be detected in the 
cytoplasm as foreign (since host cells do not produce dsRNA) by cellular 
recognition proteins, including for example RIG-I and MDA5 (reviewed in (133)). 
PAMP detection triggers signaling cascades that activate type I interferon (IFN)  
genes and pro-inflammatory cytokine genes that result in antiviral effects (133). 
Upregulation of type I IFN in host cells blocks MoMLV infection at late stages (18, 
119). Follow-up studies can be designed to test the hypothesis that the defects in 





 Understanding the mechanisms by which retroviruses regulate the 
incorporation of particle components and maintain the conserved copy numbers 
of these components is important as a possible target for antiviral therapy. 
Currently, no clinically approved antiretroviral therapies have been developed 
that target the Gag protein (reviewed in (139)). Therapeutic interventions that 
target Gag’s critical role in molecular counting during retroviral assembly 
represent a novel approach for antiretroviral drug development.  
 For example, studies with MoMLV described in this dissertation, along 
with previous studies with HIV-1 (49, 121), showed that alterations of the 
conserved Gag:Gag-Pol ratios in retroviral particles result in defects in particle 
production and infectivity. RNA aptamers represent one potential tool to disrupt 
the conserved Gag:Gag-Pol ratios. RNA aptamers are short synthetic 
oligonucleotides designed to bind specific molecular targets and represent a 
promising new class of drugs (reviewed in (96)). An RNA aptamer that bound 
and locked the RNA pseudoknot responsible for Gag stop-codon readthrough in 
the readthrough permissive conformation could potentially alter the Gag:Gag-Pol 
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